Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000569

International filing date: 17 February 2005 (17.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB

Number: 0403592.9

Filing date: 18 February 2004 (18.02.2004)

Date of receipt at the International Bureau: 01 April 2005 (01.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in

compliance with Rule 17.1(a) or (b)









The Patent Office Concept House Cardiff Road Newport South Wales NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

Stacken Hordley ...



Patents Form 1/77

THE PATENT OFFICE RM 1 8 FEB 2004 RECEIVED BY FAX

The Patent Office


18FEB04 E**SPYCHE ROO**2846 PO1/7700 **Neopoto**3592.9 ACCOUNT CHA

NP9 18H 0403592. 9

1 8 FEB 2004

Request for grant of a patent

DXM/CAL/Y1910 0403592.9 1. Your Reference Application number Lucite International UK Limited 3. Full name, address and postcode of the or each Applicant Queens Gate 15-17 Queens Terrace Country/state of incorporation SOUTHAMPTON (if applicable) Hampshire SO14 3BP Incorporated in: United Kingdom A CATALYST SYSTEM Title of the invention APPLEYARD LEES 5. Name of agent 15 CLARE ROAD Address for service in the UK to which all correspondence should HALIFAX HX1 2HY be sent 190001 Patents ADP number Date of filing Application number Country Priority claimed to: Date of filing Number of parent application 7. Divisional status claimed from: 8. Is a statement of inventorship and YES of right to grant a patent required in support of this application?



Patents Form 1/77

Page 2/2

 Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

132 (x2)

Claim(s)

13 (x2)

Abstract

1 (22)

Drawing(s)

3.00

 If you are also filing any of the following, state how many against each item

Priority documents

Translation of priority documents

Statement of inventorship and right to grant a patent (PF 7/77)

Request for a preliminary examination and search (PF 9/77)

1

Request for substantive examination (PF 10/77)

Any other documents (please specify)

11.

We request the grant of a patent on the basis of this application.
Signature Date

APPLEYARD LEES

18 February 2004

12. Contact

David Moy- 01422 330110

1

A CATALYST SYSTEM

DUPLICATE

The present invention relates to a novel catalyst system, a novel carbonylation reaction medium and a process for the carbonylation of ethylenically unsaturated compounds using a novel catalyst system.

The carbonylation of ethylenically unsaturated compounds using carbon monoxide in the presence of an alcohol or 10 water and a catalyst system comprising a Group VIII metal, palladium, and a phosphine ligand eg. phosphine cycloalkyl phosphine, aryl phosphine, pyridyl phosphine or bidentate phosphine, has been described in numerous European patents and patent applications, eg. Ep-A-0055875, EP-A-04489472, EP-A-0106379, EP-A-0235864, EP-15 A-0274795, EP-A-0499329, EP-A-0386833, EP-A-0441447, EP-A-0489472, EP-A-0282142, EP-A-0227160, EP-A-0495547 and EP-In particular, EP-A-0227160, EP-A-0495547 and EP-A-0495548 disclose that bidentate phosphine ligands provide catalyst systems which enable higher reaction 20 rates to be achieved.

WO 96/19434 discloses a bridging group in the form of an optionally substituted aryl moiety. linked to the said phosphorous atoms via available adjacent carbon atoms on the said aryl moiety. Such a ligand is more stable and leads to reaction rates which are significantly higher than those previously disclosed and produces little or no impurities for the carbonylation of ethylene. Each phosphorous atom in the said ligand is also linked to two tertiary carbon atoms.

2

However, conventional metal-catalysed reactions, such as those described in WO 96/19434 tend to suffer from the drawback that the catalyst tends to de-activate over the course of a period of continuous operation as the palladium compound is reduced to palladium metal, this contributing to the economic viability of the process. WO 01/10551 addressed this problem via the use of stabilising compounds such as polymeric dispersants in the reaction medium, thus improving in the recovery of metal which has been lost from the catalyst system.

Although catalyst systems have been developed which exhibit reasonable stability during the carbonylation process and permit relatively high reaction rates to be achieved, there still exists a need for improved catalyst systems. Suitably, the present invention aims to provide an improved catalyst for carbonylating ethylenically unsaturated compounds.

J.Mol.Cat.A 204-205 (2003) pgs 295-303 suggests that a 20 relative increase in the ligand concentration, for example by the addition of more ligand, has a detrimental effect productivity. Similar results are reported in J.Mol.Cat.A.Chem. 110 (1996) 13-23 and pgs 25 J.Mol.Cat.A.Chem. 151 (2000) pgs 47-59.

0.MOI.CRC.A.CHem. 151 (2000) pgs 47-59.

Moreover, WO-A-01/72697 describes a process for the carbonylation of pentenenitrile but teaches that there are disadvantages associated at relatively high acid:palladium ratios. The authors state that the disadvantages occur because high acid concentration conditions are corrosive and more ligand degradation results from quaternisation with the acid and the olefinic compound.

30

WO-A-01/68583 discloses a process for the carbonylation of ethylenically unsaturated compounds using phosphine-based bidentate ligands. However, this disclosure is directed towards the use of relatively low acid levels, leading to low acid:ligand values. Moreover, the ligand:metal ratios are low. WO-A-03/040159 similarly discloses low acid:ligand and ligand:metal ratios.

10 WO-A-98/45040 discloses catalyst systems comprising palladium compound and bidentate phosphorus ligands.

However, acid:ligand ratios of less than 1:1 are taught.

process the WO-A-01/72697 discloses a Finally. preparation of a 5-cyanovaleric acid by carbonylation of a 15 the points disclosure pentenenitrile. The disadvantages in using high acid concentrations and teaches towards the use of relatively low acid levels.

establish a catalyst system wherein the levels of ligand and acid are relatively high, but wherein the disadvantages of the prior art noted hereinbefore are addressed and alleviated, at least to some extent, the aforesaid being one object of the present invention.

According to the present invention there is provided a catalyst system, a process for the carbonylation of an ethylenically unsaturated compound, a reaction medium, and use as set forth in the appended claims.

Preferred features of the invention will be apparent from the dependent claims, and the description which follows.

According to a first aspect, the present invention provides a catalyst system capable of catalysing the carbonylation of an ethylenically unsaturated compound, which system is obtainable by combining:

- a) a metal of Group VIB or Group VIIIB or a compound thereof.
- b) a bidentate phosphine, arsine, or stibine ligand,
 preferably a bidentate phosphine ligand, and
 c) an acid,

wherein said ligand is present in at least a 2:1 molar excess compared to said metal or said metal in said metal compound, and that said acid is present in at least a 2:1 molar excess compared to said ligand.

Typically, component b) is a bidentate phosphine, arsine, or stibine.

20

30

Suitably, all of components a) to c) of the catalyst system can be added in situ to the reaction vessel wherein the carbonylation is to take place. Alternatively, the components a) to c) can be added sequentially in any order to form the catalyst system, or in some specified order, either directly into the vessel or outside the vessel and then added to the vessel. For instance, the acid component c) may first be added to the bidentate ligand component b), to form a protonated ligand, and then the protonated ligand can be added to the metal or compound thereof (component a)) to form the catalyst Alternatively, the ligand component b) and metal or compound thereof (component a)) can be mixed to form a

chelated metal compound, and the acid (component c)) is then added. Alternatively, any two components can be reacted together to form an intermediate moiety which is then either added to the reaction vessel and the third component added, or is first reacted with the third component and then added to the reaction vessel.

As such, the present invention is directed to a catalyst system wherein the relative molar concentrations of both the bidentate ligand and the acid are at levels in excess 10 of those previously envisaged, leading to surprising and unexpected advantages when using the catalyst system in the carbonvlation of ethylenically unsaturated compounds, and the alleviation or at least reduction of at least some of the disadvantages of the prior art systems. 15 particular, the use of a catalyst system of the present invention leads at least to a more stable increased reaction rates, and improved turnover numbers in carbonylation reactions of ethylenically unsaturated 20 compounds.

As stated above, the ligand is present in the catalyst system, or precursor thereto, in such quantity that the ratio of said ligand to the said metal (i.e. component b) component a)) is at least a 2:1 molar 25 Preferably, the ratio of said ligand to the said metal is greater than a 2:1 molar ratio, more preferably in the range 2:1 to 1000:1, even more preferably in the range 2.5:1 to 1000:1, yet more preferably in the range 3:1 to 30 1000:1, even more preferably in the range 5:1 to 750:1, still more preferably in the range 10:1 to 500:1, still more preferably in the range 20:1 to 400:1, even preferably in the range 50:1 to 250:1. most

6

preferably in the range in excess of 50:1, for example 51:1 and upwards, more specifically 51:1 to 250:1 or even to 1000:1. Alternatively, the said ratio can be in the range 15:1 to 45:1, preferably 20:1 to 40:1, more preferably 25:1 to 35:1.

As stated above, the acid is present in the catalyst system, or precursor thereto, in such quantity that the ratio of said acid to the said ligand (i.e. component c) 10 to component b)) is at least a 2:1 molar Preferably, the ratio of said acid to the said ligand is greater than a 2:1 molar ratio, more preferably in the range 2:1 to 100:1, even more preferably in the range 4:1 to 100:1, yet more preferably in the range 5:1 to 95:1, still more preferably in the range greater than 5:1 to 15 95:1, yet more preferably in the range greater than 5:1 to 75:1, more preferably in the range 10:1 to 50:1, even more preferably in the range 20:1 to 40:1, preferably in the range greater than 20:1 to 40:1 (e.g. 20 25:1 to 40:1, or 25:1 to less than 30:1), most preferably in excess of 30:1, suitably with any of the upper limits provided hereinbefore (e.g. 30:1 to 40:1).

By "acid", we mean an acid or salt thereof, and references to acid should be construed accordingly.

The advantages in working within the ligand to metal, and acid to ligand ratios, set out above are manifest in that the stability of the catalyst system is improved, as evidenced by increases in the turnover number (TON) of the metal. By improving the stability of the catalyst system, the usage of metal in the carbonylation reaction scheme is kept to a minimum.

15

20

30

7

without wishing to be bound by theory, it is believed that by working within the specific ratio ranges noted herein, it is surprisingly found that the ligand component of the catalyst system is protected against inadvertent aerial exidation (in instances where there is any ingress of air into the reaction system), and the overall stability of the catalyst system is improved, thus keeping the usage of the metal component of the catalyst system to a minimum. Moreover, the forward reaction rate of the reaction is surprisingly improved.

In effect, the level of acid should be such that for the particular bidentate ligand employed, the level of acid should be such that phosphine, arsine or stibine is fully protonated. Hence, to show the improved effects, the level of ligand should be above some minimum level, as given by the ligand:metal molar ratio, and the level of acid should be above some minimum level with respect to the level of ligand present to encourage protonation, as given by the acid:ligand molar ratio.

Preferably, the acid is present in the catalyst system, or precursor thereto, in such quantity that the molar ratio of said acid to said metal (i.e. component c) to component a)) is at least 4:1, more preferably from 4:1 to 100000:1, even more preferably 10:1 to 75000:1, yet more preferably 20:1 to 50000:1, yet still more preferably 25:1 to 50000:1, yet still more preferably 30:1 to 50000:1, yet even more preferably 40:1 to 40000:1, still more preferably 100:1 to 25000:1, yet still more preferably 200:1 to 25000:1, most preferably 550:1 to 20000:1, or greater than 2000:1 to 20000:1. Alternatively, the said ratio can be in the range 125:1 to 485:1, more preferably 150:1 to 450:1, even more preferably 175:1 to 425:1, yet

even more preferably 200:1 to 400:1, most preferably 225:1 to 375:1.

For the avoidance of any doubt, all of the aforementioned ratios and ratio ranges apply to all of the ligand embodiments set out in more detail hereinafter.

In one embodiment of the present invention, the bidentate phosphine ligand is of general formula (I)

10

$$R^{12}$$
 R^{12}
 R^{10}
 R^{10}

(I)

wherein:

Ar is a bridging group comprising an optionally substituted aryl moiety to which the phosphorus atoms are linked on available adjacent carbon atoms;

A and B each independently represent lower alkylene;

20 K, D, E and Z are substituents of the aryl moiety (Ar) and each independently represent hydrogen, lower alkyl, aryl, Het, halo, cyano, nitro, OR^{19} , $OC(O)R^{20}$, $C(O)R^{21}$, $C(O)OR^{22}$, $NR^{23}R^{24}$, $C(O)NR^{25}R^{26}$, $C(S)R^{25}R^{26}$, SR^{27} , $C(O)SR^{27}$, or -J-Q³($CR^{13}(R^{14})(R^{15})CR^{16}(R^{17})(R^{18})$ where J represents lower alkylene; or two adjacent groups selected from K, Z, D and E together with the carbon atoms of the aryl ring to which

they are attached form a further phenyl ring, which is optionally substituted by one or more substituents selected from hydrogen, lower alkyl, halo, cyano, nitro, OR^{19} , $OC(0)R^{20}$, $C(0)R^{21}$, $C(0)OR^{22}$, $NR^{23}R^{24}$, $C(0)NR^{25}R^{26}$, $C(5)R^{25}R^{26}$, SR^{27} or $C(0)SR^{27}$;

 R^{13} to R^{18} each independently represent lower alkyl, aryl, or Het;

 R^{19} to R^{27} each independently represent hydrogen, lower alkyl, aryl or Het;

10 R^1 to R^{12} each independently represent lower alkyl, aryl, or Het;

 Q^1 , Q^2 and Q^3 (when present) each independently represent phosphorous, arsenic or antimony and in the latter two cases references to phosphine or phosphorous above are amended accordingly, with preferably both Q^1 and Q^2 representing phosphorus, more preferably all of Q^1 , Q^2 and Q^3 (when present) representing phosphorus.

The bidentate phosphines of the invention should be capable of bidentate coordination to the preferred palladium atom.

Preferably, when K. D. E or Z represent $-J-Q^3(CR^{13}(R^{14})(R^{15}))CR^{16}(R^{17})(R^{16})$, the respective K. D. E or Z is on the aryl carbon adjacent the aryl carbon to which A or B is connected or, if not so adjacent, is adjacent a remaining K. D. E or Z group which itself represents $-J-Q^3(CR^{13}(R^{14})(R^{15}))CR^{16}(R^{17})(R^{16})$.

Specific but non-limiting examples of bidentate ligands within this embodiment include the following: 1,2-bis-(di-

30

10

tert-butylphosphinomethyl) benzene, 1,2-bis-(di-tertpentylphosphinomethyl) benzene, 1,2-bis-(di-tertbutylphosphinomethyl) naphthalene. Nevertheless, the
skilled person in the art would appreciate that other
bidentate ligands can be envisaged without departing from
the scope of the invention.

The term "Ar" or "aryl" when used herein, includes fivesix-to-ten preferably, to-ten-membered, carbocyclic aromatic groups, such as phenyl and naphthyl, 10 which groups are optionally substituted with, in addition to K, D, E or Z, one or more substituents selected from aryl. lower alkyl (which alkyl group may itself be optionally substituted or terminated as defined below), Het, halo, cyano, nitro, OR^{19} , $OC(O)R^{20}$, $C(O)R^{21}$, $C(O)OR^{22}$, $NR^{23}R^{24}$, C(O) $NR^{25}R^{26}$, SR^{27} , C(O) SR^{27} or C(S) $NR^{25}R^{26}$ wherein R^{19} to \mathbb{R}^{27} each independently represent hydrogen, aryl or lower alkyl (which alkyl group may itself be optionally substituted or terminated as defined below). Furthermore, 20 the aryl moiety may be a fused polycyclic group, e.g. naphthalene, biphenylene or indene.

By the term "a metal of Group VIB or Group VIIIB" in a compound of formula I we include metals such as Cr, Mo, W, Fe, Co, Ni, Ru, Rh, Os, Ir, Pt and Pd. Preferably, the metals are selected from Ni, Pt and Pd. More preferably, the metal is Pd. For the avoidance of doubt, references to Group VIB or VIIIB metals herein should be taken to include Groups 6, 8, 9 and 10 in the modern periodic table nomenclature.

The term "Het", when used herein, includes four-to-twelvemembered, preferably four-to-ten-membered ring systems,

which rings contain one or more heteroatoms selected from nitrogen, oxygen, sulphur and mixtures thereof, and which rings may contain one or more double bonds or be nonaromatic, partly aromatic or wholly aromatic in character. The ring systems may be monocyclic, bicyclic or fused. Each "Het" group identified herein is optionally substituted by one or more substituents selected from halo, cyano, nitro, oxo, lower alkyl (which alkyl group may itself be optionally substituted or terminated as defined below) OR^{19} , $OC(O)R^{20}$, $C(O)R^{21}$, $C(O)OR^{22}$, $NR^{23}R^{24}$, 10 $C(O)NR^{25}R^{26}$, SR^{27} , $C(O)SR^{27}$ or $C(S)NR^{25}R^{26}$ wherein R^{19} to R^{27} each independently represent hydrogen, aryl or lower alkyl (which alkyl group itself may be optionally substituted or terminated as defined below). The term "Het" thus includes 15 groups such as optionally substituted azetidinyl, pyrrolidinyl, imidazolyl, indolyl, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, triazolyl, oxatriazolyl, thiatriazolyl, pyridazinyl, morpholinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, piperidinyl, pyrazolyl and piperazinyl. 20 Substitution at Het may be at a carbon atom of the Het ring or, where appropriate, at one or more of the heteroatoms.

25 "Het" groups may also be in the form of an N oxide.

The term "lower alkyl" when used herein, means C₁ to C₁₀ alkyl and includes methyl, ethyl, propyl, butyl, pentyl, hexyl and heptyl groups. Unless otherwise specified, alkyl groups may, when there is a sufficient number of carbon atoms, be linear or branched, be saturated or unsaturated, be cyclic, acyclic or part cyclic/acyclic, and/or be substituted or terminated by one or more substituents

selected from halo, cyano, nitro, OR^{19} , $OC(O)R^{20}$, $C(O)R^{21}$, $C(O)R^{22}$, $C(O)R^{22}R^{24}$, $C(O)RR^{25}R^{26}$, SR^{27} , $C(O)SR^{27}$, $C(S)NR^{25}R^{26}$, aryl or Het, wherein R^{19} to R^{27} each independently represent hydrogen, aryl or lower alkyl, and/or be interrupted by one or more oxygen or sulphur atoms, or by silano or dialkylsilcon groups.

Lower alkyl groups or alkyl groups which R1, R2, R3, R4, R^{5} , R^{6} , R^{7} , R^{8} , R^{9} , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , \mathbb{R}^{19} , \mathbb{R}^{20} , \mathbb{R}^{21} , \mathbb{R}^{22} , \mathbb{R}^{23} , \mathbb{R}^{24} , \mathbb{R}^{25} , \mathbb{R}^{26} , \mathbb{R}^{27} , K, D, E and Z may 10 represent and with which aryl and Het may be substituted, may, when there is a sufficient number of carbon atoms, be linear or branched, be saturated or unsaturated, cyclic, acyclic or part cyclic/acyclic, and/or interrupted by one or more of oxygen or sulphur atoms, or 15 by silano or dialkylsilicon groups, and/or be substituted by one or more substituents selected from halo, cyano, nitro, OR^{19} , $OC(0)R^{20}$, $C(0)R^{21}$, $C(0)OR^{22}$, $NR^{23}R^{24}$, $C(0)NR^{25}R^{26}$, SR^{27} , $C(0)SR^{27}$, $C(S)NR^{25}R^{26}$, aryl or Het wherein R^{19} to R^{27} each independently represent hydrogen, aryl or lower 20 alkyl.

Similarly, the term "lower alkylene" which A, B and J (when present) represent in a compound of formula I, when used herein, includes C₁ to C₁₀ groups which are bonded to other moieties at least at two places on the group and is otherwise defined in the same way as "lower alkyl".

Halo groups with which the above-mentioned groups may be substituted or terminated include fluoro, chloro, bromo and iodo.

Where a compound of a formula herein contains an alkenyl group, cis (E) and trans (Z) isomerism may also occur. The present invention includes the individual stereoisomers of the compounds of any of the formulas defined herein and, tautomeric forms appropriate, the individual where 5 thereof, together with mixtures thereof. Separation of diastereoisomers or cis and trans isomers may be achieved by fractional conventional techniques, e.g. chromatography or H.P.L.C. οf crystallisation, stereoisomeric mixture of a compound one of the formulas or a suitable salt or derivative thereof. An individual enantiomer of a compound of one of the formulas may also corresponding optically be prepared from a. intermediate or by resolution, such as by H.P.L.C. of the corresponding racemate using a suitable chiral support or 15 by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, appropriate.

20

10

All stereoisomers are included within the scope of the process of the invention.

It will be appreciated by those skilled in the art that the compounds of formula I may function as ligands that 25 coordinate with the Group VIB or Group VIIIB metal or compound thereof in the formation of the catalyst system of the invention. Typically, the Group VIB or Group VIIIB metal or compound thereof coordinates to the one or more 30 phosphorous, arsenic and/or antimony atoms of the compound of formula I.

Preferably, R1 to R18 each independently represent lower or aryl. More preferably, R1 to independently represent C_1 to C_6 alkyl, $C_1\text{-}C_6$ alkyl phenyl (wherein the phenyl group is optionally substituted as defined herein) or phenyl (wherein the phenyl group is optionally substituted as defined herein). Even more preferably, R^1 to R^{18} each independently represent C_1 to C_6 alkyl, which is optionally substituted as defined herein. Most preferably, R1 to R18 each represent non-substituted C1 to C6 alkyl such as methyl, ethyl, n-propyl, iso-propyl, 10 iso-butyl, tert-butyl, pentyl, hexyl and n-butyl, cyclohexyl.

Alternatively, or additionally, each of the groups R¹ to R³, R⁴ to R⁶, R⁷ to R⁹, R¹⁰ to R¹², R¹³ to R¹⁵ or R¹⁶ to R¹⁸ together independently may form cyclic structures such as 1-norbornyl or 1-norbornadienyl. Further examples of composite groups include cyclic structures formed between R¹-R¹⁸. Alternatively, one or more of the groups may represent a solid phase to which the ligand is attached.

In a particularly preferred embodiment of the present invention R¹, R⁴, R⁷, R¹⁰, R¹³ and R¹⁶ each represent the same lower alkyl, aryl or Het moiety as defined herein, R², R⁵, R⁸, R¹⁴, R¹⁴ and R¹⁷ each represent the same lower alkyl, aryl or Het moiety as defined herein, and R³, R⁶, R⁹, R¹², R¹⁵ and R¹⁸ each represent the same lower alkyl, aryl or Het moiety as defined herein. More preferably R¹, R⁴, R⁷, R¹⁰, R¹³ and R¹⁶ each represent the same C₁-C₆ alkyl, particularly non-substituted C₁-C₆ alkyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tertbutyl, pentyl, hexyl or cyclohexyl; R², R⁵, R⁸, R¹¹, R¹⁴ and R¹⁷ each independently represent the same C₁-C₆ alkyl as

15

20

25

defined above; and R³, R⁶, R⁹, R¹², R¹⁵ and R¹⁸ each independently represent the same C₁-C₆ alkyl as defined above. For example: R¹, R⁴, R⁷, R¹⁰, R¹³ and R¹⁶ each represent methyl; R², R⁵, R⁸, R¹¹, R¹⁴ and R¹⁷ each represent ethyl; and, R³, R⁶, R⁹, R¹², R¹⁵ and R¹⁸ each represent n-butyl or n-pentyl.

In an especially preferred embodiment of the present invention each R^1 to R^{18} group represents the same lower alkyl, aryl, or Het moiety as defined herein. Preferably, each R^1 to R^{18} represents the same C_1 to C_6 alkyl group, particularly non-substituted C_1 - C_6 alkyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tertbutyl, pentyl, hexyl and cyclohexyl. Most preferably, each R^1 to R^{18} represents methyl.

In the compound of formula I, preferably each Q^1 , Q^2 and Q^3 (when present) are the same. Most preferably, each Q^1 , Q^2 and Q^3 (when present) represents phosphorous.

Preferably, in the compound of formula I, A, B and J (when present) each independently represent C_1 to C_6 alkylene which is optionally substituted as defined herein, for example with lower alkyl groups. Preferably, the lower alkylene groups which A, B and J (when present) represent are non-substituted. A particular preferred lower alkylene which A, B and J may independently represent is $-CH_2-$ or $-C_2H_4-$. Most preferably, each of A, B and J (when present) represent the same lower alkylene as defined herein, particularly $-CH_2-$.

Freferably, in the compound of formula I when K, D, E or Z does not represent $-J-Q^3(CR^{13}(R^{14})(R^{15}))CR^{16}(R^{17})(R^{18})$, K, D,

E or Z represents hydrogen, lower alkyl, phenyl or lower alkylphenyl. More preferably, K, D, E or Z represent hydrogen, phenyl, C_1 - C_6 alkylphenyl or C_1 - C_6 alkyl, such as methyl, ethyl, propyl, butyl, pentyl and hexyl. Most preferably, K, D, E or Z represents hydrogen.

Preferably, in the compound of formula I when K, D, E and Z together with the carbon atoms of the aryl ring to which they are attached do not form a phenyl ring, K, D, E and Z each independently represent hydrogen, lower alkyl, phenyl or lower alkylphenyl. More preferably, K, D, E and Z each independently represent hydrogen, phenyl, C₁-C₆ alkylphenyl or C₁-C₆ alkyl, such as methyl, ethyl, propyl, butyl, pentyl and hexyl. Even more preferably, K, D, E and Z represent the same substituent. Most preferably, they represent hydrogen.

Preferably, in the compound of formula I when K, D, E or Z does not represent $-J-Q^3(CR^{13}(R^{14})(R^{15}))CR^{16}(R^{17})(R^{18})$ and K, D, E and Z together with the carbon atoms of the aryl ring to which they are attached do not form a phenyl ring, each of K, D, E and Z represent the same group selected from hydrogen, lower alkyl, aryl, or Het as defined herein; particularly hydrogen or C_1-C_6 alkyl (more particularly unsubstituted C_2-C_6 alkyl), especially hydrogen.

Preferably, in the compound of formula I when two of K, D, E and Z together with the carbon atoms of the aryl ring to which they are attached form a phenyl ring, then the phenyl ring is optionally substituted with one or more substituents selected from aryl, lower alkyl (which alkyl group may itself be optionally substituted or terminated as defined below), Het, halo, cyano, nitro, OR^{18} , $OC(O)R^{20}$,

 $C(0)R^{21}$, $C(0)OR^{22}$, $NR^{23}R^{24}$, $C(0)NR^{25}R^{26}$, SR^{27} , $C(0)SR^{27}$ or $C(S)NR^{25}R^{26}$ wherein R^{19} to R^{27} each independently represent hydrogen or lower alkyl (which alkyl group may itself be optionally substituted or terminated as defined herein). More preferably, the phenyl ring is not substituted by any substituents i.e. it bears hydrogen atoms only.

Preferred compounds of formula I include those wherein:

- 10 A and B each independently represent unsubstituted C_1 to C_6 alkylene;
- K, D, Z and E each independently represent hydrogen, C1-C6 -Jalkyl, $C_1 - C_6$ alkylphenyl or phenyl, $Q^3 (CR^{13} (R^{14}) (R^{15})) CR^{16} (R^{17}) (R^{18})$ where J represents 15 unsubstituted C1 to C6 alkylene; or two of K, D, Z and E together with the carbon atoms of the aryl ring to which they are attached form a phenyl ring which is optionally substituted by one or more substituents selected from lower alkyl, phenyl or lower alkylphenyl. 20

 R^1 to R^{16} each independently represent C_1 to C_6 alkyl, phenyl or C_1 to C_6 alkylphenyl.

25 Further preferred compounds of formula I include those wherein:

A and B both represent -CH2- or C2H4, particularly CH2;

30 K, D, Z and E each independently represent hydrogen, C_1 - C_6 alkyl phenyl or C_1 - C_6 alkyl or -J- $Q^3(CR^{13}(R^{14})(R^{15}))CR^{16}(R^{17})(R^{18})$ where J is the same as A; or two of K, D, E and Z together with the carbon atoms of the

25

aryl ring to which they are attached form an unsubstituted phenyl ring;

 R^1 to R^{18} each independently represent C_1 to C_6 alkyl;

Still further preferred compounds of formula I include those wherein:

 R^1 to R^{18} are the same and each represents C_1 to C_6 alkyl, 10 particularly methyl.

Still further preferred compounds of formula I include those wherein:

15 K, D, Z and E are each independently selected from the group consisting of hydrogen or C₁ to C₅ alkyl, particularly where each of K, D, Z and E represent the same group, especially where each of K, D, Z and E represent hydrogen; or

K represents $-CH_2-Q^3(CR^{13}(R^{14})(R^{15}))CR^{16}(R^{17})(R^{18})$ and D, Z and E are each independently selected from the group consisting of hydrogen or C_1 to C_6 alkyl, particularly where both D and E represent the same group, especially where D, Z and E represent hydrogen.

Especially preferred specific compounds of formula I include those wherein:

each R¹ to R¹² is the same and represents methyl;

A and B are the same and represent -CH₂-;

K, D, Z and E are the same and represent hydrogen.

In a still further embodiment, at least one $(CR^xR^yR^2)$ group attached to Q^1 and/or Q^2 , i.e. $CR^1R^2R^3$, $CR^4R^5R^6$, $CR^7R^8R^9$, or $CR^{10}R^{11}R^{12}$, may instead be represented by the group (Ad) wherein:

5

Ad each independently represent an optionally substituted adamantyl or congressyl radical bonded to the phosphorous atom via any one of its tertiary carbon atoms, the said optional substitution being by one or more substituents selected from hydrogen, lower alkyl, halo, cyano, nitro, 10 OR^{19} , $OC(O)R^{20}$, $C(O)R^{21}$, $C(O)OR^{22}$, $NR^{23}R^{24}$, $C(O)NR^{25}$ R^{26} , C(S)R25R26, SR27 or C(O)SR27; or if both (CR*RYR2) groups attached to either or both Q^1 and/or Q^2 , or Q^3 (if present) together with either Q^1 or Q^2 (or Q^3) as appropriate, form 2-phosphaoptionally substituted 15 tricyclo[3.3.1.1{3,7}]decyl group or derivative thereof, or form a ring system of formula

20

wherein

 \mathbb{R}^{49} , and \mathbb{R}^{54} , each independently represent hydrogen, lower alkyl or aryl;

25 R^{50} to R^{53} , when present, each independently represent hydrogen, lower alkyl, aryl or Het; and

Y represents oxygen, sulfur or $N-R^{55}$, and R^{55} , wher present, represents hydrogen, lower alkyl or aryl.

25

30

20

In this embodiment, formula I may be represented as:

$$(Ad)_{S}(CR^{7}R^{8}R^{9})_{T}Q^{2}-A-(K,D)Ar(E,Z)-B-Q^{1}(Ad)_{u}(CR^{1}R^{2}R^{3})_{v}$$

wherein Ar, A, B, K, D, E and Z, Q^1 , Q^2 , and Q^3 , and R^1 to R^{27} are as defined hereinbefore except that K, D, E and Z may represent $-J-Q^3(\mathrm{Ad})_*(\mathrm{CR}^{13}(\mathrm{R}^{14})(\mathrm{R}^{15})_*$ instead of -J-

 $Q^3(CR^{13}(R^{14})(R^{15}))CR^{16}(R^{17})(R^{18})$ and Ad is as defined above,

S & U = 0, 1 or 2 provided that $S + U \ge 1$; T & V = 0, 1 or 2 provided that $T + V \le 3$; W & X = 0, 1 or 2.

15 In addition to the preferred embodiments for R¹ to R¹⁸, Q¹ to Q³, A, B, J (when present), K, D, E or Z, R¹⁹ to R²⁷, noted hereinbefore, all of which equally apply to the present embodiment where at least one (Ad) group is present, the following also applies.

Further preferred compounds of formula I include those wherein:

A and B both represent -CH2- or -C2H4-, particularly -CH2-;

K, D, Z and E each independently represent hydrogen, C_1 - C_5 alkyl phenyl or C_1 - C_6 alkyl or -J- Q^3 (Ad) $_w$ (CR¹³(R¹⁴)(R¹⁵)) $_x$ where J is the same as A; or two of K, D, E and Z together with the carbon atoms of the aryl ring to which they are attached form an unsubstituted phenyl ring;

 R^1 to R^3 , R^7 to R^9 , and R^{13} to R^{15} (when present) each independently represent C_1 to C_6 alkyl, and the total

number of (Ad) groups attached to Q^1 and Q^2 is ≥ 3 , i.e. $S + U \ge 3$, and W and X = 0, 1 or 2.

Still further preferred compounds of formula I include those wherein:

 R^1 to R^3 , R^7 to R^9 and R^{13} to R^{15} (when present) are the same and each represents C_1 to C_6 alkyl, particularly methyl, and the total number of (Ad) groups attached to Q^1 and Q^2 is ≥ 3 , i.e. $S + U \ge 3$.

Still further preferred compounds of formula I include those wherein:

15 K, D, Z and E are each independently selected from the group consisting of hydrogen or C_1 to C_6 alkyl, particularly where each of K, D, Z and E represent the same group, especially where each of K, D, Z and E represent hydrogen; or

20

25

10

K represents $-CH_2-Q^3$ (Ad) $_W$ (CR¹³ (R¹⁴) (R¹⁵) $_X$ and D, Z and E are each independently selected from the group consisting of hydrogen or C_1 to C_6 alkyl, particularly where both D and E represent the same group, especially where D, Z and E represent hydrogen, wherein W and X = 0, 1 or 2.

Especially preferred specific compounds of formula I include those wherein:

each R^1 to R^3 , and R^7 to R^9 is the same and represents methyl or the total number of (Ad) groups attached to Q^1 and Q^2 is 2, i.e. S+U=2;

A and B are the same and represent $-CH_2-$;

K, D, Z and E are the same and represent hydrogen.

Especially preferred specific compounds of formula I include those wherein Ad is joined to Q_1 or Q_2 at the same position in each case. Preferably $S \ge 1$ and $U \ge 1$, more preferably, S = 2 and $U \ge 1$ or vice versa, most preferably $S \ge U = 2$, wherein S is the number of (Ad) groups attached to Q^2 and U is the number of (Ad) groups attached to Q^2 .

Specific but non-limiting examples of bidentate ligands 10 following: 1,2 the within this embodiment include bis (diadamantylphosphinomethyl) benzene, 1,2 bis(di-3,5dimethyladamantylphosphinomethyl)benzene, bis(di-5~ 1,2 tert-butyladamantaylphosphinomethyl)benzene, 1,2 adamantyl tert-butyl-phosphinomethyl) benzene, 1,2 bis(di-1-1-diamantanephosphinomethyl) benzene, [(diadamantylphosphinomethyl)-2-(di-tertbutylphosphinomethyl)]benzene, 1-(di-tert-

butylphosphinomethyl)-2-

30

20 (dicongressylphosphinomethyl) benzene, 1-(di-tert-butylphosphinomethyl)-2-(phospha-adamantylphosphinomethyl) benzene, 1-

(diadamantylphosphinomethyl)-2-(phospha-

adamantylphosphinomethyl) benzene, 1-(tert-butyladamantyl) -

25 2-(di-adamantyl)-(phosphinomethyl)benzene and 1-[(P-(2,2,6,6,-tetra-methylphosphinan-4-one)phosphinomethyl)]2-(phospha-adamantylphosphinomethyl)benzene.

Nevertheless, the skilled person in the art would appreciate that other bidentate ligands can be envisaged without departing from the scope of the invention.

In a yet further embodiment, the bidentate phosphine ligand is of general formula (III).

$$K^1$$
 A_1
 A_2
 A_1
 A_2
 A_1
 A_2
 A_1
 A_2
 A_1
 A_1
 A_2
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_2
 A_2
 A_1
 A_2
 A_2
 A_2
 A_1
 A_2
 A_1
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_1
 A_2
 A_1
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_1
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_2
 A_1
 A_2
 A_1
 A_2
 A_2
 A_1

wherein:

5

 A_1 and A_2 , and A_3 , A_4 and A_5 (when present), each independently represent lower alkylene;

 K^{1} is selected from the group consisting of hydrogen, lower alkyl, aryl, Het, halo, cyano, nitro, $-OR^{19}$, -OC(O) R^{20} , -C(O) R^{21} , -C(O) OR^{22} , -N(R^{23}) R^{24} , -C(O)N(R^{25}) R^{26} , -C(S)(R^{27}) R^{28} , -SR²⁹, -C(O)SR³⁰, -CF₃ or -A₃-Q³(X⁵)X⁶;

D¹ is selected from the group consisting of hydrogen, 15 lower alkyl, aryl, Het, halo, cyano, nitro, $-OR^{19}$, $-OC(O)R^{20}$, $-C(O)R^{21}$, $-C(O)OR^{22}$, $-N(R^{23})R^{24}$, $-C(O)N(R^{25})R^{26}$, $-C(S)(R^{27})R^{28}$, $-SR^{29}$, $-C(O)SR^{30}$, $-CF_3$ or $-A_4-Q^4(X^7)X^8$;

E¹ is selected from the group consisting of hydrogen, 20 lower alkyl, aryl, Het, halo, cyano, nitro, $-OR^{19}$, -OC(O)R²⁰, $-C(O)R^{21}$, $-C(O)OR^{22}$, $-N(R^{23})R^{24}$, $-C(O)N(R^{25})R^{26}$, -C(S)(R²⁷)R²⁸, $-SR^{29}$, $-C(O)SR^{30}$, $-CF_3$ or $-A_5-Q^5(X^9)X^{10}$;

or both D¹ and E¹ together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an optionally substituted phenyl ring:

5 X¹ represents CR¹(R²)(R³), congressyl or adamantyl, X² represents CR⁴(R⁵)(R⁶), congressyl or adamantyl, or X¹ and X² together with Q² to which they are attached form an optionally substituted 2-phosphatricyclo[3.3.1.1{3.7}]decyl group or derivative thereof, or X¹ and X² together with Q² to which they are attached form a ring system of formula IIIa

X³ represents CR³(R³)(R³), congressyl or adamantyl, X⁴

15 represents CR¹(R¹¹)(R¹²), congressyl or adamantyl, or X³

and X⁴ together with Q¹ to which they are attached form an optionally substituted 2-phosphatricyclo[3.3.1.1{3,7}]decyl group or derivative thereof, or X³ and X⁴ together with Q¹ to which they are attached form a ring system of formula IIIb

 X^5 represents $CR^{13}(\mathbb{R}^{14})$ (\mathbb{R}^{15}) , congressyl or adamantyl, X^6 represents $CR^{16}(\mathbb{R}^{17})$ (\mathbb{R}^{18}) , congressyl or adamantyl, or X^5

and X^6 together with Q^3 to which they are attached form an optionally substituted 2-phosphatricyclo[3.3.1.1{3,7}]decyl group or derivative thereof, or X^5 and X^6 together with Q^3 to which they are attached form a ring system of formula IIIc

X⁷ represents CR³¹(R³²)(R³³), congressyl or adamantyl, X⁵
represents CR³⁴(R³⁵)(R³⁶), congressyl or adamantyl, or X⁷
and X⁸ together with Q⁴ to which they are attached form an
10 optionally substituted 2-phosphatricyclo[3.3.1.1{3.7}]decyl group or derivative thereof,
or X⁷ and X⁸ together with Q⁴ to which they are attached form a ring system of formula IIId

15 X⁹ represents CR³⁷(R³⁸)(R³⁹), congressyl or adamantyl, X¹⁰ represents CR⁴⁰(R⁴¹)(R⁴²), congressyl or adamantyl, or X⁹ and X¹⁰ together with Q⁵ to which they are attached form an optionally substituted 2-phosphatricyclo[3.3.1.1.{3,7}]decyl group or derivative thereof, or X⁹ and X¹⁰ together with Q⁵ to which they are attached form a ring system of formula IIIe

and in this yet further embodiment, Q^1 and Q^2 , and Q^3 , Q^4 and Q^5 (when present), each independently represent phosphorus, arsenic or antimony;

M represents a Group VIB or VIIIB metal or metal cation thereof:

10 L₁ represents an optionally substituted cyclopentadienyl, indenyl or aryl group;

L₂ represents one or more ligands each of which are independently selected from hydrogen, lower alkyl, alkylaryl, halo, CO, P(R⁴³)(R⁴⁴)R⁴⁵ or N(R⁴⁵)(R⁴⁷)R⁴⁸;

 R^1 to R^{18} and R^{31} to R^{42} , when present, each independently represent hydrogen, lower alkyl, aryl, halo or Het:

20 R¹⁹ to R³⁰ and R⁴³ to R⁴⁸, when present, each independently represent hydrogen, lower alkyl, anyl or Het;

 \mathbb{R}^{49} , \mathbb{R}^{54} and \mathbb{R}^{55} , when present, each independently represent hydrogen, lower alkyl or aryl;

 R^{50} to R^{53} , when present, each independently represent hydrogen, lower alkyl, aryl or Het;

 Y^1 , Y^2 , Y^3 , Y^4 and Y^5 , when present, each independently represent oxygen, sulfur or N-R⁵⁵;

n = 0 or 1;

5

and m = 0 to 5;

provided that when n=1 then m equals 0, and when n equals 0 then m does not equal 0.

Preferably in a compound of formula III when both K^1 represents $-A_3-Q^3(X^5)X^6$ and E^1 represents $-A_5-Q^5(X^9)X^{10}$, then D^1 represents $-A_4-Q^4(X^7)X^8$.

Preferably, in this embodiment, R^1 to R^{18} and R^{31} to R^{42} , 15 when present, each independently represent hydrogen, optionally substituted C1 to C6 alkyl, C1-C6 alkyl phenyl (wherein the phenyl group is optionally substituted as defined herein), trifluoromethyl or phenyl (wherein the phenyl group is optionally substituted as defined herein). 20 Even more preferably, R^1 to R^{18} and R^{31} to R^{42} , when present, each independently represent hydrogen, C1 to C6 alkyl, which is optionally substituted as defined herein, trifluoromethyl or optionally substituted phenyl. Even more preferably, R1 to R15 and R31 to R42, when present each independently represent hydrogen, non-substituted C_1 to C_6 alkyl or phenyl which is optionally substituted with one or more substituents selected from non-substituted C_1 to C₆ alkyl or OR¹⁹ where R¹⁹ represents hydrogen unsubstituted C_1 to C_6 alkyl. More preferably, R^1 to R^{16} 30 and R31 to R42, when present, each independently represent hydrogen or non-substituted C_1 to C_6 alkyl such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tertbutyl, pentyl, hexyl and cyclohexyl, especially methyl.

Most preferably, R¹ to R¹⁸ and R³¹ to R⁴² when present, each
independently represent non-substituted C₁ to C₆ alkyl such
as methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl and cyclohexyl,
especially methyl.

Alternatively, or additionally, one or more of the groups \mathbb{R}^1 to \mathbb{R}^3 , \mathbb{R}^4 to \mathbb{R}^6 , \mathbb{R}^7 to \mathbb{R}^9 , \mathbb{R}^{10} to \mathbb{R}^{12} , \mathbb{R}^{13} to \mathbb{R}^{15} , \mathbb{R}^{16} to \mathbb{R}^{18} , \mathbb{R}^{31} to \mathbb{R}^{33} , \mathbb{R}^{34} to \mathbb{R}^{36} , \mathbb{R}^{37} to \mathbb{R}^{39} or \mathbb{R}^{40} to \mathbb{R}^{42} (when present) together with the carbon atom to which they are attached independently may form cyclic alkyl structures such as 1-norbornyl or 1-norbornadienyl.

15 Alternatively, or additionally, one or more of the groups R^1 and R^2 , R^4 and R^5 , R^7 and R^8 , R^{10} and R^{11} , R^{13} and R^{14} , R^{15} and R^{17} , R^{31} and R^{32} , R^{34} and R^{35} , R^{37} and R^{36} or R^{40} and R^{41} (when present) together with the carbon atom to which they are attached independently may form a cyclic alkyl 20 structures, preferably a C_5 to C_7 cyclic alkyl structure such as cyclohexyl and cyclopentyl, and R^3 , R^6 , R^9 , R^{12} , R^{15} , R^{18} , R^{33} , R^{36} , R^{39} and R^{42} (when present) each independently represent hydrogen, lower alkyl, trifluoromethyl or aryl as defined above, particularly 25 non-substituted C_1 to C_6 alkyl and hydrogen, especially non-substituted C_1 to C_6 alkyl.

In an especially preferred embodiment, each of R^1 to R^{18} and R^{31} to R^{42} , when present, do not represent hydrogen. Suitably, such an arrangement means Q^1 , Q^2 , Q^3 , Q^4 and Q^5 are bonded to a carbon atom of X^1 to X^{10} , respectively, which bears no hydrogen atoms.

Preferably, R^{2} , R^{4} , R^{7} , R^{10} , R^{13} , R^{16} , R^{31} , R^{34} , R^{37} and R^{40} (when present), each represent the same substituent as defined herein; R^2 , R^5 , R^8 , R^{11} , R^{14} , R^{17} , R^{32} , R^{35} , R^{38} and \mathbb{R}^{41} (when present), each represent the same substituent as defined herein; and R^3 , R^6 , R^9 , R^{12} , R^{15} , R^{18} , R^{35} , R^{36} , R^{39} and \mathbb{R}^{42} (when present), each represent the substituent as defined herein. More preferably R^1 , R^4 , R^7 , R^{10} , R^{12} , R^{16} , R^{31} , R^{34} , R^{37} and R^{40} (when present) each represent the same $C_1\text{-}C_6$ alkyl, particularly non-10 substituted C_1-C_6 alkyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, hexyl or cyclohexyl, or trifluoromethyl; \mathbb{R}^2 , \mathbb{R}^5 , \mathbb{R}^6 , \mathbb{R}^{11} , \mathbb{R}^{14} , \mathbb{R}^{17} , \mathbb{R}^{32} , \mathbb{R}^{35} , \mathbb{R}^{38} and \mathbb{R}^{41} (when present), each independently represent the same $C_1 - C_6$ alkyl as defined above. trifluoromethyl; and R^3 , R^6 , R^9 , R^{12} , R^{15} , R^{18} , R^{33} , R^{36} , R^{39} and \mathbb{R}^{42} (when present), each independently represent the same $C_1\text{-}C_6$ alkyl as defined above, or trifluoromethyl. For example: R^1 , R^4 , R^7 , R^{10} , R^{13} and R^{16} (when present) each represent methyl; R^2 , R^5 , R^8 , R^{11} , R^{14} and R^{17} each represent 20 ethyl (when present); and, R^3 , R^6 , R^9 , R^{12} , R^{15} and R^{18} (when present) each represent n-butyl or n-pentyl.

In an especially preferred embodiment each \mathbb{R}^1 to \mathbb{R}^{18} and ${\tt R}^{31}$ to ${\tt R}^{42}$ group (when present) represents the same 25 substituent as defined herein. Preferably, each R1 to R18 and R^{31} to R^{42} group represents the same C_{1} to C_{6} alkyl group, particularly non-substituted $C_1 \sim C_6$ alkyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, and cyclohexyl, hexyl pentyl, tert-butyl, 30 trifluoromethyl. Most preferably, each R^1 to R^{18} and R^{31} to represents non-substituted C1-C6 alkyl, R^{42} group particularly methyl.

.: ' -

10

15

30

The term adamantyl when used herein means an adamantyl group which may be bonded to Q^1 , Q^2 , Q^3 , Q^4 and Q^5 , 2. or position 1 <u>i</u>n respectively, Tricyclo[3.3.1.1.{3,7}]decyl is the systematic name for an adamantyl group, suitably Q1, Q2, Q3, Q4 and respectively, may be bonded to the 1 position or 2 position of one or two tricyclo[3.3.1.1.{3,7}]decyl groups. Preferably, Q^2 and Q^2 , and Q^3 , Q^4 and Q^5 , when present, is bonded to a tertiary carbon of one or more adamantyl groups. Suitably, when the adamantyl group represents unsubstituted adamantyl, Q^1 and Q^2 , and Q^3 , Q^4 and Q5 when present are preferably bonded to the 1 position of one or more tricyclo[3.3.1.1{3,7}]decyl groups i.e. the carbon atom of the adamantyl group bears no hydrogen atom.

The adamantyl group may optionally comprise, besides hydrogen atoms, one or more substituents selected from lower alkyl, $-OR^{19}$, $-OC(O)R^{20}$, halo, nitro, $-C(O)R^{21}$, aryl, $-N(R^{23})R^{24}$, $-C(0)N(R^{25})R^{26}$, cyano, $-C(O)OR^{22}$ 20 $-P(R^{56})R^{57}$, $-PO(R^{58})(R^{59})$, $-PO_3H_2$, $-C(S)(R^{27})R^{28}$, -CF3, -PO(OR⁶⁰)(OR⁶¹), or -SO₃R⁶², wherein R¹⁹, R²⁰, R²¹, R²², R²³, R^{24} , R^{25} , R^{26} , R^{27} , R^{28} , lower alkyl, cyano and aryl are as defined herein and R^{56} to R^{62} each independently represent hydrogen, lower alkyl, aryl or Het. 25

Suitably, when the adamantyl group is substituted with one or more substituents as defined above, highly preferred substituents include unsubstituted C1 to C8 alkyl, -OR19, - $OC(O)R^{20}$, phenyl, $-C(O)OR^{22}$, fluoro, $-SO_3H$, $-N(R^{23})R^{24}$, 30 $-P(R^{56})R^{57}$, $-C(O)N(R^{25})R^{26}$ and $-PO(R^{58})(R^{59})$, $-CF_3$, wherein R^{19} represents hydrogen, unsubstituted C1-C8 alkyl or phenyl, \mathbb{R}^{20} , \mathbb{R}^{22} , \mathbb{R}^{23} , \mathbb{R}^{24} , \mathbb{R}^{25} , \mathbb{R}^{25} each independently represent

hydrogen or unsubstituted $C_1\text{--}C_\theta$ alkyl, R^{56} to $R^{53},\ R^{56}$ each independently represent unsubstituted C_1 - C_8 alkyl phenyl.

the adamantyl group may comprise, Suitably, hydrogen atoms, up to 10 substituents as defined above. preferably up to 5 substituents as defined above, more substituents as defined above. 3 preferably up to Suitably, when the adamantyl group comprises, besides hydrogen atoms, one or more substituents as defined 10 identical. substituent is each preferably Preferred substituents are unsubstituted C_1 - C_8 alkyl and trifluoromethyl, particularly unsubstituted C1-C8 alkyl A highly preferred adamantyl group such as methyl. comprises hydrogen atoms only i.e. the adamantyl group is 15 not substituted.

Preferably, when more than one adamantyl group is present in a compound of formula III, each adamantyl group is identical. 20

By the term 2-phospha-tricyclo[3.3.1.1.{3,7}]decyl group 2-phospha-adamantyl group formed combination of X^1 and X^2 together with Q^2 to which they are a 2-phospha-adamantyl group formed combination of X3 and X4 together with Q1 to which they are a 2-phospha-adamantyl group formed combination of X5 and X6 together with Q3 to which they are attached, a 2-phospha-adamantyl group formed by combination of X^7 and X^8 together with Q^4 to which they are 30 attached and a 2-phospha-adamantyl group formed by the combination of X9 and X10 together with Q5 to which they are attached, wherein Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is in the 2position of the adamantyl group of which it forms an integral part and each of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 represents phosphorus.

The 2-phospha-tricyclo[3.3.1.1.{3,7}]decyl group (referred to as 2-phospha-adamantyl group herein) may optionally comprise, beside hydrogen atoms, one or more substituents. substituents those include substituents Suitable defined herein in respect of the adamantyl group. Highly preferred substituents include lower alkyl, particularly 10 methyl. especially alkyl, unsubstituted $C_1 - C_B$ -OR19 wherein R19 is as defined herein trifluoromethyl, particularly unsubstituted C_1 - C_2 alkyl or aryl, and 4dodecylphenyl. When the 2-phospha-adamantyl group includes more than one substituent, preferably each substituent is identical.

Preferably, the 2-phospha-adamantyl group is substituted on one or more of the 1, 3, 5 or 7 positions with a substituent as defined herein. More preferably, the 2-20 phospha-adamantyl group is substituted on each of the 1, 3 and 5 positions. Suitably, such an arrangement means the phosphorous atom of the 2-phospha-adamantyl bonded to carbon atoms in the adamantyl skeleton having no hydrogen atoms. Most preferably, the 2-phospha-adamantyl 25 group is substituted on each of the 1, 3, 5 and 7 positions. When the 2-phospha-adamantyl group includes more than 1 substituent preferably each substituent is substituents preferred Especially identical. trifluoromethyl, and alky1 $C_1 - C_8$ 30 unsubstituted particularly unsubstituted C_1 - C_8 alkyl such as methyl.

2-phospha-adamantyl group Preferably, the additional heteroatoms, other than the 2-phosphorous atom, in the 2-phospha-adamantyl skeleton. Suitable additional heteroatoms include oxygen and sulphur atoms, especially oxygen atoms. More preferably, the 2-phospha-adamantyl group includes one or more additional heteroatoms in the 9 and 10 positions. Even more preferably, the 2phospha-adamantyl group includes an additional heteroatom in each of the 6, 9 and 10 positions. Most preferably, when the 2-phospha-adamantyl group includes two or more 2-phospha-adamantyl the in heteroatoms additional heteroatoms are the additional each of skeleton. An especially preferred 2-phospha-adamantyl identical. group, which may optionally be substituted with one or more substituents as defined herein, includes an oxygen 15 atom in each of the 6, 9 and 10 positions of the 2phospha-adamantyl skeleton.

Highly preferred 2-phospha-adamantyl groups as defined 2-phospha-1,3,5,7-tetramethy1-6,9,10include herein 20 2-phospha-1,3,5-trimethyl-6,9,10group, trioxadamantyl 2-phospha-1,3,5,7group, trioxadamantyl tetra(trifluoromethyl)-6,9,10-trioxadamantyl group, and 2phospha-1,3,5-tri(trifluoromethyl)-6,9,10-trioxadamantyl 2-phospha-adamantyl preferably, the Most group. 25 2-phospha-1,3,5,7-tetramethyl-6,9,10selected trioxadamantyl group or 2-phospa-1,3,5,-trimethyl-6,9,10trioxadamantyl group.

30 Preferably, when more than one 2-phospha-adamantyl group is present in a compound of formula III, each 2-phospha-adamantyl group is identical.

The above definition of the term "2-phosphatricyclo[3.3.1.1.{3,7}]decyl group" applies equally to the group when it is present in formula I but wherein X^n in formula III, i.e. X^1 , X^2 , X^3 ... X^{10} , is denoted $CR^xR^yR^z$, i.e. $CR^1R^2R^3$,... $CR^{16}R^{17}R^{18}$, in formula I.

The term congressyl when used herein means a congressyl group (also known as diamantyl group) which may be bonded to Q^1 , Q^2 , Q^3 , Q^4 and Q^5 respectively. Preferably, Q^1 and Q^2 , and Q^3 , Q^4 and Q^5 , when present, are bonded to one of the tertiary carbon atoms of the congressyl groups. Suitably, when the congressyl group is unsubstituted, Q^1 and Q^2 , and Q^3 , Q^4 and Q^5 when present, are preferably bonded to the 1-position of one or more congressyl groups.

The congressyl group may optionally comprise, beside hydrogen atoms, one or more substituents. Suitable substituents include those substituents as defined herein in respect of the adamantyl group. Highly preferred substituents include unsubstituted C₁-C₅ alkyl groups, particularly methyl, and trifluoromethyl. Most preferably, the congressyl group is unsubstituted and comprises hydrogen atoms only.

25 Preferably, when more than one congressyl group is present in a compound of formula III, each congressyl group is identical.

Preferably, where one or more ring systems of formula IIIa, IIIb, IIIc, IIId or IIIe are present in a compound of formula III, R⁵⁰ to R⁵³ each independently represent lower alkyl, aryl or Het, which groups are optionally substituted and/or terminated as defined herein. Such an

15

20

arrangement means Q^2 , Q^1 , Q^3 , Q^4 and Q^5 of the ring system of formula IIIa to IIIe, respectively, is not bonded to a carbon atom bearing a hydrogen atom. Even more preferably, R^{50} to R^{53} each independently represent optionally substituted C_1 - C_6 alkyl, preferably non-substituted C_1 - C_6 alkyl, phenyl optionally substituted with non-substituted C_1 - C_6 alkyl or OR^{19} where R^{19} represents non-substituted C_1 - C_6 alkyl, or trifluoromethyl. Even more preferably R^{50} to R^{53} each represent the same group as defined herein, particularly non-substituted C_1 - C_6 alkyl, especially methyl.

Preferably, where one or more ring system of formula IIIa to IIIe are present in a compound of formula III, R^{49} and R^{54} each independently represent optionally substituted C_1 - C_6 alkyl, preferably non-substituted C_1 - C_6 alkyl, phenyl optionally substituted with non-substituted C_1 - C_6 alkyl or OR^{19} where R^{19} represents non-substituted C_1 - C_6 alkyl, trifluoromethyl or hydrogen. More preferably, R^{49} and R^{54} represent the same group as defined herein, especially hydrogen.

Preferably, where one or more ring systems of formula IIIa to IIIe are present in a compound of formula III, Y¹ to Y⁵ are identical. Most preferably, each of Y¹ to Y⁵ represents oxygen. Preferably, where more than one ring system of formula IIIa to IIIe is present in a compound of formula III, each such ring system is identical.

30 Preferred embodiments of the present invention include those wherein:

- X^1 represents $CR^1(R^2)(R^3)$, X^2 represents $CR^4(R^5)(R^6)$, X^3 represents $CR^7(R^8)(R^9)$ and X^4 represents $CR^{10}(R^{11})(R^{12})$;
- X^1 represents $CR^1(R^2)(R^3)$, X^2 represents adamantyl, X^3 represents $CR^7(R^8)(R^9)$ and X^4 represents adamantyl;
 - X^1 represents $CR^1(R^2)(R^3)$, X^2 represents congressyl, X^3 represents $CR^7(R^8)(R^9)$ and X^4 represents congressyl;
- 10 $X^{\frac{1}{4}}$ represents $CR^{1}(R^{2})(R^{3})$, X^{2} represents $CR^{4}(R^{5})(R^{6})$, and X^{3} and X^{4} together with Q^{1} to which they are attached form a ring system of formula IIIb or a 2-phospha-adamantyl group;
- 15 X^1 represents $CR^1(R^2)(R^3)$, X^2 represents adamantyl, X^3 and X^4 together with Q^1 to which they are attached form a ring system of formula IIIb or a 2-phospha-adamantyl group;
- X^1 represents $CR^1(R^2)(R^3)$, X^2 represents congressyl, X^3 and X^4 together with Q^1 to which they are attached form a ring system of formula IIIb or a 2-phospha-adamantyl group;
 - X^1 to X^4 each independently represent adamantyl;
- 25 X1 to X4 each independently represent congressyl;
 - \mathbf{X}^1 and \mathbf{X}^2 each independently represent adamantyl and \mathbf{X}^3 and \mathbf{X}^4 each independently represent congressyl;
- 30 X^1 and X^3 independently represent adamantyl and X^2 and X^4 independently represent congressyl;

 X^1 and X^2 independently represent adamanty[, X^3 represents $CR^7(\mathbb{R}^9)$ (\mathbb{R}^9) and X^4 represents $CR^{10}(\mathbb{R}^{11})$ (\mathbb{R}^{12});

 X^1 and X^2 independently represent congressyl, X^3 represents $CR^7(\mathbb{R}^8)$ (\mathbb{R}^9) and X^4 represents $CR^{10}(\mathbb{R}^{11})$ (\mathbb{R}^{12});

 X^1 and X^2 independently represent adamantyl, and X^2 and X^4 together with Q^1 to which they are attached form a ring system of formula IIIb or a 2-phospha-adamantyl group;

 X^1 and X^2 independently represent congressyl, and X^3 and X^4 together with Q^1 to which they are attached form a ring system of formula IIIb or a 2-phospha-adamantyl group;

- 15 X^1 and X^2 together with Q^2 to which they are attached form a ring system of formula IIIa, and X^3 and X^4 together with Q^1 to which they are attached form a ring system of formula IIIb;
- X^1 and X^2 together with Q^2 to which they are attached form a 2-phospha-adamantyl group, and X^3 and X^4 together with Q^1 to which they are attached form a 2-phospha-adamantyl group;
- 25 Highly preferred embodiments of the present invention include those wherein:

 X^1 represents $CR^1(R^2)(R^3)$, X^2 represents $CR^4(R^5)(R^6)$, X^3 represents $CR^7(R^6)(R^5)$ and X^4 represents $CR^{10}(R^{11})(R^{12})$;

 X^1 represents $CR^1(R^2)(R^3)$, X^2 represents adamantyl, X^3 represents $CR^7(R^8)(R^9)$ and X^4 represents adamantyl;

 X^1 represents $CR^1(\mathbb{R}^2)$ (\mathbb{R}^3), X^2 represents congressyl, X^3 represents $CR^7(\mathbb{R}^8)$ (\mathbb{R}^9) and X^4 represents congressyl;

 X^1 to X^4 each independently represent adamantyl;

X1 to X4 each independently represent congressyl;

X¹ and X² together with Q² to which they are attached form a ring system of formula IIIa, and X³ and X⁴ together with 10 Q¹ to which they are attached form a ring system of formula IIIb;

X¹ and X² together with Q² to which they are attached form a 2-phospha-adamantyl group, and X³ and X⁴ together with Q¹ to which they are attached form a 2-phospha-adamantyl group;

preferably in a compound of formula III, X¹ is identical to X³ and X² is identical to X⁴. More preferably, X¹ is identical to X³ and X⁵, X⁷ and X⁵ when present, and X² is identical to X⁴ and X⁶, X⁸ and X¹⁰ when present. Even more preferably, X¹ to X⁴ are identical. Most preferably, X¹ to X⁴ are identical to each of X⁶ to X¹⁰ when present.

Preferably, in the compound of formula III, X¹ and X² represent identical substituents, X³ and X⁴ represent identical substituents, X⁵ and X⁶ (when present) represent identical substituents, X⁷ and X⁸ (when present) represent identical substituents, and X⁹ and X¹⁰ (when present) represent identical substituents.

Preferably, in a compound of formula III, K^1 represents - $A_3-Q^3\left(X^5\right)X^6$, hydrogen, lower alkyl, -CF3, phenyl or lower

alkyl phenyl. More preferably, K^1 represents $-A_3-Q^3(X^5)X^6$, hydrogen, unsubstituted C_1-C_6 alkyl, unsubstituted phenyl, trifluoromethyl or C_1-C_6 alkyl phenyl.

5 In a particular preferred embodiment K^1 in a compound of formula III represents hydrogen.

In an alternative embodiment where K^1 does not represent hydrogen, K^1 represents $-A_3 - Q^3(X^5)X^6$. Preferably, X^5 is identical to X^2 or X^4 .

More preferably, X^5 is identical to both X^3 and X^1 , and X^6 is identical to both X^2 and X^4 . Even more preferably, $-A_3 - Q^3(X^6)X^6$ is identical to either $-A_1 - Q^2(X^1)X^2$ or $-A_2 - Q^1(X^3)X^4$. Most preferably, $-A_3 - Q^3(X^5)X^6$ is identical to both $-A_1 - Q^2(X^1)X^2$ and $-A_2 - Q^1(X^3)X^4$.

Most preferably, K^1 represents hydrogen in a compound of formula III.

Preferably, in the compound of formula III, D1 represents 20 -A₄-Q⁴(X⁷)X⁸, hydrogen, lower alkyl, CF₃, phenyl or lower alkylphenyl, and E^1 represents $-A_5-Q^5(X^9)X^{10}$, hydrogen, lower alkyl, CF3, phenyl or lower alkylphenyl, or D1 and E1 together with the carbons of the cyclopentadienyl ring to 25 which they are attached form an optionally substituted phenyl ring. More preferably, D^1 represents $-A_4-Q^4(X^7)X^8$, hydrogen, phenyl, C1-C6 alkylphenyl, unsubstituted C1-C6 alkyl, such as methyl, ethyl, propyl, butyl, pentyl and E^1 represents $-A_5-Q^5(X^9)X^{10}$, hydrogen, hexyl, or CF3; phenyl, $C_1\text{-}C_6$ alkylphenyl, unsubstituted $C_1\text{-}C_6$ alkyl such 30 as methyl, ethyl, propyl, butyl, pentyl and hexyl, or - CF_3 ; or both D^1 and E^1 together with the carbon atoms of the cyclopentadienyl ring to which they are attached form

a phenyl ring which is optionally substituted with one or more groups selected from phenyl, C_1 - C_6 alkylphenyl, unsubstituted C_1 - C_6 alkyl or $-CF_3$.

- Suitably, when D¹ and E¹ together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an optionally substituted phenyl ring, the metal M or cation thereof is attached to an indenyl ring system.
- In a particular preferred embodiment, D^1 in a compound of formula III, represents hydrogen.

In an alternative embodiment where D^1 does not represent hydrogen, D^1 represents $-A_4-Q^4(X^7)X^8$. Preferably X^8 is identical to X^4 or X^2 , and X^7 is identical to X^1 or X^3 . More preferably, X^8 is identical to both X^4 and X^2 , and X^7 is identical to X^1 and X^3 . Even more preferably, $-A_4-Q^4(X^7)X^8$ is identical to either $-A_1-Q^2(X^1)X^2$ or $-A_2-Q^1(X^3)X^4$. Most preferably, $-A_4-Q^4(X^7)X^8$ is identical to both $-A_2-Q^1(X^3)X^4$, and $-A_3-Q^3(X^5)X^5$ if present.

In a particular preferred embodiment, E^1 in a compound of formula III represents hydrogen.

In an alternative embodiment where E¹ does not represent hydrogen, E¹ represents $-A_5 - Q^5(X^9)X^{10}$. Preferably X¹0 is identical to X⁴ or X², and X9 is identical to X¹ or X³. More preferably, X¹0 is identical to both X⁴ and X², and X⁵ is identical to X¹ and X³. Even more preferably, $-A_5 - Q^5(X^9)X^{10}$ is identical to either $-A_1 - Q^2(X^1)X^2$ or $-A_3 - Q^1(X^3)X^4$. Most preferably, $-A_5 - Q^5(X^9)X^{10}$ is identical to both $-A_1 - Q^2(X^1)X^2$ and $-A_3 - Q^1(X^3)X^4$, and $-A_3 - Q^3(X^5)X^5$ and $-A_4 - Q^4(X^7)X^8$ if present.

Preferably, in the compound of formula III, when D^1 and E^1 together with the carbon atoms of the cyclopentadienyl ring to which they are attached do not form an optionally substituted phenyl ring, each of K^1 , D^1 and E^1 represent an identical substituent.

In an alternative preferred embodiment, D¹ and E¹ together with the carbons of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring.

Highly preferred embodiments of compounds of formula III include those wherein:

15 K^1 , D^1 and E^1 are identical substituents as defined herein, particularly where K^1 , D^1 and E^1 represent hydrogen;

K¹ represents hydrogen, and D¹ and E¹ together with the carbons of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring;

 K^1 represents $-A_3-Q^3(X^6)X^6$ as defined herein and both D^1 and E^1 represent H_3

- 25 K^1 represents $-A_3-Q^3(X^5)X^6$ as defined herein and D^1 and E^1 together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring;
- 30 K¹ represents $-A_3-Q^3(X^5)X^6$, D¹ represents $-A_4-Q^4(X^7)X^8$ and E¹ represents $-A_5-Q^5(X^5)X^{10}$.

Especially preferred compounds of formula III include those where both D^1 and E^1 represent hydrogen or D^1 and E^1 together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring, particularly those compounds where both D^1 and E^1 represent hydrogen.

Preferably, in the compound of formula III, A₁ and A₂, and A₃, A₄ and A₅ (when present), each independently represent C₁ to C₆ alkylene which is optionally substituted as defined herein, for example with lower alkyl groups. Suitably, A₁ and A₂, and A₃, A₄ and A₅ (when present) may include a chiral carbon atom. Preferably, the lower alkylene groups which A₁ to A₅ may represent are non-substituted. A particular preferred lower alkylene, which A₁ to A₅ may independently represent, is -CH₂- or -C₂H₄-. Most preferably, each of A₁ and A₂, and A₃, A₄ and A₅ (when present), represent the same lower alkylene as defined herein, particularly -CH₂-.

20

15

In the compound of formula III, preferably each Q^1 and Q^2 , and Q^3 , Q^4 and Q^5 (when present) are the same. Most preferably, each Q^1 and Q^2 , and Q^3 , Q^4 and Q^5 (when present), represents phosphorus.

25

30

It will be appreciated by those skilled in the art that the compounds of formula III may function as ligands that coordinate with the Group VIB or Group VIIIB metal or compound thereof in the formation of the catalyst system of the invention. Typically, the Group VIB or Group VIIIB metal or compound thereof coordinates to the one or more phosphorus, arsenic and/or antimony atoms of the compound of formula III. It will be appreciated that the compounds

of formula III may be referred to broadly as "metallocenes".

Suitably, when n=1 and L_1 represents an optionally the group, indenyl cyclopentadienyl or substituted contain two either may formula III compounds of cyclopentadienyl rings, two indenyl rings or one indenyl and one cyclopentadienyl ring (each of which ring systems may optionally be substituted as described herein). Such compounds may be referred to as "sandwich compounds" as the metal M or metal cation thereof is sandwiched by the two ring systems. The respective cyclopentadienyl and/or indenyl ring systems may be substantially coplanar with respect to each other or they may be tilted with respect to each other (commonly referred to as bent metallocenes).

Alternatively, when $n \neq 1$ and L_1 represents aryl, the compounds of the invention may contain either one cyclopentadienyl or one indenyl ring (each of which ring systems may optionally be substituted as described herein) and one aryl ring which is optionally substituted as defined herein. Suitably, when n = 1 and L_1 represents aryl then the metal M of the compounds of formula III as defined herein is typically in the form of the metal cation.

In a particularly preferred embodiment of the present invention, in a compound of formula III, n=1, L_1 is as defined herein and m=0.

Preferably, when n=1 in the compound of formula III, L_1 represents cyclopentadienyl, indenyl or aryl ring each of which rings are optionally substituted by one or more

0094997 18-Feb-04 03:04

30

5

10

15

20

25

44

substituents selected from hydrogen, lower alkyl, halo, nitro, $-OR^{19}$, $-OC(O)R^{20}$, $-C(O)R^{21}$, $-C(O)OR^{22}$, $-N(R^{23})R^{24}$, $-C(O)N(R^{25})R^{26}$, $-C(S)(R^{27})R^{28}$ $-SR^{29}$, $-C(O)SR^{30}$, -CF3 or ferrocenyl (by which we mean the cyclopentadienyl, indenyl or aryl ring which L_1 may represent is bonded directly to the cyclopentadienyl ring of the ferrocenyl group), wherein R^{19} to R^{30} is as defined herein. More preferably, if the cyclopentadienyl, indenyl or aryl ring which L_1 may represent is substituted it is preferably substituted with one or more substituents selected from 10 unsubstituted C_1-C_6 alkyl, halo, cyano, $-OR^{19}$, $-OC(O)R^{20}$, $-C(O)R^{21}$, $-C(O)OR^{22}$, $-N(R^{23})R^{24}$ where R^{19} , R^{20} , R^{21} , R^{22} , R^{23} and \mathbb{R}^{24} each independently represent hydrogen or C_1 - C_6 Even more preferably, if the cyclopentadienyl, is indemyl or aryl ring which L_1 may represent is substituted, it is preferably substituted with one or more substituents selected from unsubstituted C_1 - C_5 alkyl.

Preferably, when n = 1, L₁ represents cyclopentadienyl,
indenyl, phenyl or napthyl optionally substituted as
defined herein. Preferably, the cyclopentadienyl, indenyl,
phenyl or napthyl groups are unsubstituted. More
preferably, L₁ represents cyclopentadienyl, indenyl or
phenyl, each of which rings are unsubstituted. Most
preferably, L₁ represents unsubstituted cyclopentadienyl.

Alternatively, when n=0, the compounds of the invention contain only one cyclopentadienyl or indenyl ring (each of which ring systems may optionally be substituted as described herein). Such compounds may be referred to as "half sandwich compounds". Preferably, when n=0 then m represents 1 to 5 so that the metal M of the compounds of formula III has an 18 electron count. In other words, when

metal M of the compounds of formula III is iron, the total number of electrons contributed by the ligands L_2 is typically five.

In a particularly preferred alternative embodiment of the present invention, in a compound of formula III, n=0, L_2 is as defined herein and m=3 or 4, particularly 3.

Preferably, when n is equal to zero and m is not equal to zero in a compound of formula III, L_2 represents one or 10 more ligands each of which are independently selected from lower alkyl, halo, -CO, -P(\mathbb{R}^{43}) (\mathbb{R}^{44}) \mathbb{R}^{45} or -N(\mathbb{R}^{46}) (\mathbb{R}^{47}) \mathbb{R}^{48} . More preferably, L_2 represents one or more ligands each of which are independently selected from unsubstituted C_1 to C_4 alkyl, halo, particularly chloro, -CO, -P(\mathbb{R}^{43})(\mathbb{R}^{44}) \mathbb{R}^{45} or 15 R43 to R48 are independently $-N(R^{46})(R^{47})R^{48}$ wherein selected from hydrogen, unsubstituted C_1 to C_6 alkyl or aryl, such as phenyl.

Suitably, the metal M or metal cation thereof in the 20 compounds of formula III is typically bonded to the cyclopentadienyl ring(s), the cyclopentadienyl moiety of the indenyl ring(s) if present, the aryl ring if present, if present. Typically, ligands $\mathbf{L_2}$ and/or cyclopentadienyl ring or the cyclopentadienyl moiety of 25 the indenyl ring exhibits a pentahapto bonding mode with however other bonding modes between the the metal: cyclopentadienyl ring or cyclopentadienyl moiety of the indenyl ring and the metal, such as trihapto coordination, are also embraced by the scope of the present invention. 30

30

Most preferably, in a compound of formula III, n=1, m=0 and L_1 is defined herein, particularly unsubstituted cyclopentadienyl.

5 Preferably M represents a Group VIB or VIIIB metal. In other words the total electron count for the metal M is 18.

Preferably, in the compound of formula III, M represents

Cr, Mo, Fe, Co or Ru, or a metal cation thereof. Even more preferably, M represents Cr, Fe, Co or Ru or a metal cation thereof. Most preferably, M is selected from a group VIIIB metal or metal cation thereof. An especially preferred Group VIIIB metal is Fe. Although the metal M as defined herein may be in a cationic form, preferably it carries essentially no residual charge due to coordination with L1 and/or L2 as defined herein.

Especially preferred compounds of formula III include 20 those wherein:

(1) X¹ represents CR¹(R²)(R³), X² represents CR⁴(R⁵)(R⁵), X³ represents CR²(R³)(R³), X⁴ represents CR¹(R¹¹)(R¹²), wherein each of R¹ to R¹² independently represents unsubstituted C₁-C₆ alkyl or trifluoromethyl, particularly where each of R¹ to R¹² is identical, especially where each of R¹ to R¹² represents unsubstituted C₁-C₆ alkyl, particularly methyl;
A₁ and A₂ are the same and represent -CH₂-;
K², D¹ and E¹ are the same and represent hydrogen or unsubstituted C₁-C₆ alkyl, particularly hydrogen;
Q¹ and Q² both represent phosphorus;

M represents Fe;

n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.

- X^{1} represents $CR^{1}(R^{2})(R^{3})$, X^{2} represents $CR^{4}(R^{5})(R^{6})$, (2) 5 X^3 represents $CR^7(R^8)(R^9)$, X^4 represents $CR^{10}(R^{11})(R^{12})$; K^1 represents $-CH_2-Q^3(X^5)X^6$ wherein X^5 represents $CR^{13}(R^{14})(R^{15})$ and K^{6} represents $CR^{16}(R^{17})(R^{18})$; R¹⁸ independently represent \mathbb{R}^1 to of each or trifluoromethyl, alkyl $C_1 - C_6$ unsubstituted 10 particularly where each of R1 to R18 is identical, especially where each of R¹ to R¹⁸ represents unsubstituted C1-C6 alkyl, particularly methyl; A_1 and A_2 are the same and represent $-CH_2-1$ Q1, Q2 and Q3 each represent phosphorus; 15 D1 and E1 are the same and represent hydrogen or unsubstituted C1-C6 alkyl, particularly hydrogen; M represents Fe; represents cyclopentadienyl, $\mathbf{L}_{\mathbf{1}}$ 1 and \mathbf{n} particularly unsubstituted cyclopentadienyl, and m = 20 o.
- X^1 represents $CR^1(\mathbb{R}^2)$ (\mathbb{R}^3), X^2 represents $CR^4(\mathbb{R}^5)$ (\mathbb{R}^6), (3) X^3 represents $CR^7(R^8)(R^9)$, X^4 represents $CR^{10}(R^{11})(R^{12})$; represents $-CH_2-Q^3(X^5)X^6$ wherein X^5 represents 25 $\mathbb{CR}^{13}(\mathbb{R}^{14})$ (\mathbb{R}^{15}) and \mathbb{X}^6 represents $\mathbb{CR}^{16}(\mathbb{R}^{17})$ (\mathbb{R}^{18}); $\mathbf{R}^{\mathtt{lB}}$ independently represent R^{L} to alkyl or trifluoromethyl, unsubstituted C1-C6 particularly where each of R1 to R18 is identical, especially where each of R1 to R18 30 unsubstituted C1-C6 alkyl, particularly methyl; A_1 and A_2 are the same and represent $-CH_2-$; Q^{1} , Q^{2} and Q^{3} each represent phosphorus;

D¹ and E¹ together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring;
M represents Fe;

- n = 1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m = 0.
- X^1 represents $CR^1(R^2)(R^3)$, X^2 represents $CR^4(R^5)(R^6)$, (4) X^3 represents $CR^7(\mathbb{R}^8)$ (\mathbb{R}^8), X^4 represents $CR^{10}(\mathbb{R}^{11})$ (\mathbb{R}^{12}), 10 wherein each of R1 to R12 independently represent unsubstituted C1-C6 alkyl or trifluoromethyl, particularly where each of R^1 to R^{12} is identical, especially where each of R1 to R12 represents 15 unsubstituted C1-C6 alkyl, particularly methyl; A₁ and A₂ are the same and represent -CH₂-; Q1 and Q2 both represent phosphorus: K^2 represents hydrogen or C_1 - C_6 alkyl, particularly hydrogen; D1 and E1 together with the carbon atoms of the 20 cyclopentadienyl ring to which they are attached
- n = 1 and L_1 represents cyclopentadienyl, 25 particularly unsubstituted cyclopentadienyl, and m=0.

form an unsubstituted phenyl ring;

M represents Fe:

(5) X¹ represents CR¹(R²)(R³), X² represents CR⁴(R⁵)(R⁶), X³ represents CR⁷(R⁸)(R⁹), X⁴ represents CR¹⁰(R¹¹)(R¹²);

E¹ represents -CH₂-Q⁵(X⁹)X¹⁰ wherein X⁹ represents CR³⁷(R³⁸)(R³⁹) and X¹⁰ represents CR⁴⁰(R⁴¹)(R⁴²);

each of R¹ to R¹² and R³⁷ to R⁴² independently represent unsubstituted C₁-C₆ alkyl or

٥.

trifluoromethyl, particularly where each of R^1 to R^{12} and R^{37} to R^{42} is identical, especially where each of R^1 to R^{12} and R^{37} to R^{42} represents unsubstituted C_1 - C_6 alkyl, particularly methyl;

 A_1 and A_2 are the same and represent $-CH_2-$; Q^1 , Q^2 and Q^5 each represent phosphorus; D^1 and K^1 are the same and represent hydrogen or unsubstituted C_1-C_6 alkyl, particularly hydrogen; M represents Fe;

n = 1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0

 X^1 represents $CR^1(\mathbb{R}^2)$ (\mathbb{R}^3), X^2 represents $CR^4(\mathbb{R}^5)$ (\mathbb{R}^6), (6) X^3 represents $CR^7(R^8)(R^9)$, X^4 represents $CR^{10}(R^{11})(R^{12})$; 15 represents -CH2-Q3(X5)X6 wherein X5 represents $CR^{13}(R^{14})(R^{15})$ and X^6 represents $CR^{16}(R^{17})(R^{18})$; represents $-CH_2-Q^4(X^7)X^8$ wherein X^7 represents $CR^{31}(R^{32})$ (R^{33}) and X^8 represents $CR^{34}(R^{35})$ (R^{36}); E^1 represents $-CH_2-Q^5(X^9)X^{10}$ wherein X^9 represents 20 $CR^{37}(R^{38})(R^{39})$ and X^{10} represents $CR^{40}(R^{41})(R^{42})$; each of \mathbb{R}^1 to \mathbb{R}^{18} and \mathbb{R}^{31} to \mathbb{R}^{42} independently unsubstituted C1-C5 represent trifluoromethyl, particularly where each of \mathbb{R}^1 to \mathbb{R}^{18} and R^{31} to R^{42} is identical, especially where each 25 of \mathbb{R}^1 to \mathbb{R}^{18} and \mathbb{R}^{31} to \mathbb{R}^{42} represents unsubstituted C1-C6 alkyl, particularly methyl; A_1 and A_2 are the same and represent -CH₂-; Q^1 , Q^2 , Q^3 , Q^4 and Q^5 each represent phosphorus M represents Fe; 30 L₁ represents cyclopentadienyl, and particularly unsubstituted cyclopentadienyl, and m =

- (7) X^1 , X^2 , X^3 and X^4 independently represent adamantyl, especially where X^1 to X^4 represent the same adamantyl group;
- A₁ and A₂ are the same and represent -CH₂-;

 K¹, D¹ and E¹ are the same and represent hydrogen or unsubstituted C₁-C₆ alkyl, particularly hydrogen;

 Q¹ and Q² both represent phosphorus;

 M represents Fe;
- (6) X¹, X², X³ and X⁴ independently represent adamantyl, especially where X² to X⁴ represent the same adamantyl group;
 K¹ represents -CH₂-Q³(X⁵)X⁶ wherein X⁵ and X⁶ independently represent adamantyl, especially where X¹ to X⁵ represent the same adamantyl group;
- A₁ and A₂ are the same and represent $-CH_2-$; Q^1 , Q^2 and Q^3 each represent phosphorus; D^1 and E^1 are the same and represent hydrogen or unsubstituted C_1-C_6 alkyl, particularly hydrogen; M represents Fe;
- n = 1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m = 0.
- (9) X^1 , X^2 , X^3 and X^4 independently represent adamantyl, especially where X^1 to X^4 represent the same adamantyl group;

 K^1 represents $-CH_2-Q^3(X^5)X^6$ wherein X^5 and X^6 independently represent adamantyl, especially where X^1 to X^6 represent the same adamantyl group; A_1 and A_2 are the same and represent $-CH_2-$;

Q¹, Q² and Q³ each represent phosphorus;
D¹ and E¹ together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring;

M represents Fa;

n = 1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m = 0.

(10) X¹, X², X³ and X⁴ independently represent adamantyl, especially where X¹ to X⁴ represent the same adamantyl group;

A₁ and A₂ are the same and represent -CH₂-;

Q¹ and Q² both represent phosphorus;

K¹ represents hydrogen or unsubstituted C₁-C₆ alkyl, particularly hydrogen;

D¹ and E¹ together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring;

M represents Fe;

n = 1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.

(11) X¹, X², X³ and X⁴ independently represent adamantyl;
30 K¹ represents -CH₂-Q³(X⁵)X⁶ wherein X⁵ and X⁶ independently represent adamantyl;
D¹ represents -CH₂-Q⁴(X⁷)X⁸ wherein X⁷ and X⁸ independently represents adamantyl;

E¹ represents $-CH_2-Q^5(X^9)X^{10}$ wherein X^5 and X^{10} independently represents adamantyl, especially where X^1 to X^{10} represent the same adamantyl group; A_1 and A_2 are the same and represent $-CH_2-$; Q^1 , Q^2 , Q^3 , Q^4 and Q^5 each represent phosphorus; M represents Fe; M represents M represe

m = 1 and L_1 represents cyclopentacienyl, particularly unsubstituted cyclopentacienyl, and m = 0.

10

5

- (12) X¹ and X² together with Q² to which they are attached represents 2-phospha-adamantyl;
 X³ and X⁴ together with Q¹ to which they are attached represents 2-phospha-adamantyl;
- A₁ and A₂ are the same and represent -CH₂-;

 K¹, D¹ and E¹ are the same and represent hydrogen or unsubstituted C₁-C₆ alkyl, particularly hydrogen;

 Q¹ and Q² both represent phosphorus;

 M represents Fe;
- n=1 and L_1 represents, cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.
- (13) X¹ and X² together with Q² to which they are attached represents 2-phospha-adamentyl;

 X³ and X⁴ together with Q¹ to which they are attached represents 2-phospha-adamentyl;

 K¹ represents -CH₂-Q³(X⁵)X⁶ wherein X⁵ and X⁶ together with Q³ to which they are attached represents 2-phospha-adamantyl;

 A₁ and A₂ are the same and represent -CH₂-;

 Q², Q² and Q³ each represent phosphorus;

 D^1 and E^1 are the same and represent hydrogen or unsubstituted $C_1 - C_6$ alkyl, particularly hydrogen; M represents Fe;

n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.

- (14) X^1 and X^2 together with Q^2 to which they are attached represents 2-phospha-adamantyl;
- 10 X^3 and X^4 together with Q^1 to which they are attached represents 2-phospha-adamantyl; $K^1 \text{ represents } -CH_2-Q^3\left(X^5\right)X^6 \text{ wherein } X^5 \text{ and } X^6 \text{ together with } Q^3 \text{ to which they are attached represents 2-}$

phospha-adamantyl; A_1 and A_2 are the same and represent -CH₂-; Q^1 , Q^2 and Q^3 each represent phosphorus;

D¹ and E¹ together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring;

20 M represents Fe;

n = 1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m = 0.

25 (15) X¹ and X² together with Q² to which they are attached represents 2-phospha-adamantyl;

X³ and X⁴ together with Q¹ to which they are attached

 A_1 and A_2 are the same and represent $-CH_2$ -;

30 Q¹ and Q² both represent phosphorus;

represents 2-phospha-adamantyl;

 K^1 represents hydrogen or unsubstituted C_1 - C_6 alkyl, particularly hydrogen;

D' and E' together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring;

M represents Fe;

- n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.
- (16) X¹ and X² together with Q² to which they are attached represents 2-phospha-adamantyl;

 X³ and X⁴ together with Q¹ to which they are attached represents 2-phospha-adamantyl;

 K¹ represents -CH₂-Q³(X⁵)X⁶ wherein X⁵ and X⁶ together with Q³ to which they are attached represents 2-phospha-adamantyl;

 D¹ represents -CH₂-Q⁴(X⁷)X⁸ wherein X⁷ and X⁸ together with Q⁴ to which they are attached represents 2-phospha-adamantyl;
 - represents -CH₂-Q⁵(X⁹)X¹⁰ wherein X⁹ and X¹⁰
 together with Q⁵ to which they are attached represents 2-phospha-adamantyl;

 A_1 and A_2 are the same and represent -CH2-; $Q^1,\ Q^2,\ Q^3,\ Q^4 \ \text{and}\ Q^5 \ \text{each represent phosphorus}$ M represents Fe;

- 25 n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.
- (17) X^1 and X^2 together with Q^2 to which they are attached form a ring system of formula IIIa, X^3 and X^4 together with Q^1 to which they are attached form a ring system of formula IIIb, wherein Y^1 and Y^2 both represent oxygen, R^{50} to R^{53} are independently

20

selected from unsubstituted C_1-C_6 alkyl or CF_3 , and R^{49} and R^{54} represent hydrogen;

 A_1 and A_2 are the same and represent -CH2-;

 K^1 , D^1 and E^1 are the same and represent hydrogen or unsubstituted $C_1\text{-}C_6$ alkyl, particularly hydrogen,

Q1 and Q2 both represent phosphorus;

M represents Fe;

n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl

10 (referred to as puc) and m = 0.

- (18) X¹ and X² together with Q² to which they are attached form a ring system of formula IIIa, X³ and X⁴ together with Q¹ to which they are attached form a ring system of formula IIIb, wherein Y¹ and Y² both represent oxygen, R⁵⁰ to R⁵³ are independently selected from unsubstituted C₁-C₆ alkyl or CF₃, and R⁴⁹ and R⁵⁴ represent hydrogen;
 - K^1 represents $-CH_2-Q^3(X^5)X^6$ wherein X^5 and X^6 together with Q^3 to which they are attached form a ring system of formula IIIc, wherein Y^3 represents oxygen, R^{50} to R^{53} are independently selected from hydrogen, unsubstituted C_1-C_6 alkyl or CF_3 and R^{49} and R^{54} represent hydrogen;
- A₁ and A₂ are the same and represent $-CH_2-;$ $Q^1,\ Q^2 \ \text{and}\ Q^3 \ \text{each represent phosphorus};$ $D^1 \ \text{and}\ E^1 \ \text{are the same and represent hydrogen or}\ C_1-C_6 \ \text{alkyl, particularly hydrogen};$ $M \ \text{represents Fe};$
- n = 1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m = 0.

15

 X^{1} and X^{2} together with Q^{2} to which they are attached (19)form a ring system of formula IIIa, X^3 and X^4 together with Q1 to which they are attached form a ring system of formula IIIb, wherein Y^1 and Y^2 both represent oxygen, R^{50} to R^{53} are independently 5 selected from unsubstituted C_1 - C_6 alkyl or CF_3 , and R49 and R54 represent hydrogen; K^1 represents $-CH_2-Q^3(X^5)X^6$ wherein X^5 and X^6 together with Q3 to which they are attached form a ring system of formula IIIc, wherein Y^3 represents oxygen, R^{50} to R^{53} are independently selected from unsubstituted C_1-C_6 alkyl or CF_3 , and R^{49} and R^{54} represent hydrogen;

> A_1 and A_2 are the same and represent -CH₂-; Q^1 , Q^2 and Q^3 each represent phosphorus;

 \mathfrak{D}^1 and \mathtt{E}^1 together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring;

M represents Fe;

- represents cyclopentadienyl, $\mathbf{L_1}$ 1 and 20 particularly unsubstituted cyclopentadienyl, and m =α.
- \mathbf{X}^{1} and \mathbf{X}^{2} together with \mathbf{Q}^{2} to which they are attached (20) form a ring system of formula IIIa, X^3 and X^4 25 together with Q^1 to which they are attached form a ring system of formula IIIb, wherein Y^1 and Y^2 both represent oxygen, R^{50} to R^{53} are independently selected from unsubstituted C_1 - C_6 alkyl or CF_3 , and R49 and R54 represent hydrogen; 30 A_1 and A_2 are the same and represent -CH₂-; Q1 and Q2 both represent phosphorus;

 K^1 represents hydrogen or unsubstituted C_1 - C_6 alkyl, particularly hydrogen;

D¹ and E¹ together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring;

M represents Fe;

n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.

10

15

20

25

5

(21) X^1 and X^2 together with Q^2 to which they are attached form a ring system of formula IIIa, X^3 and X^4 together with Q^1 to which they are attached form a ring system of formula IIIb, wherein Y^1 and Y^2 both represent oxygen, R^{50} to R^{53} are independently selected from unsubstituted C_1 - C_6 alkyl or CF_3 , and R^{49} and R^{54} represent hydrogen;

 K^1 represents $-CH_2-Q^3(X^5)X^6$ wherein X^5 and X^6 together with Q^3 to which they are attached form a ring system of formula IIIc, wherein Y^3 represents oxygen, R^{50} to R^{53} are independently selected from unsubstituted C_1-C_6 alkyl or CF_3 , and R^{49} and R^{54} represent hydrogen;

 D^1 represents $-CH_2-Q^4(X^7)X^8$ wherein X^7 and X^6 together with Q^4 to which they are attached form a ring system of formula IIIc, wherein Y^3 represents oxygen, R^{50} to R^{53} are independently selected from unsubstituted C_1-C_6 alkyl or CF_3 , and R^{49} and R^{54} represent hydrogen;

 E^1 represents $-CH_2-Q^5(X^9)\,X^{10}$ wherein X^9 and X^{10} together with Q^5 to which they are attached form a ring system of formula IIIe, wherein Y^5 represents oxygen, and R^{50} to R^{53} are independently selected

from unsubstituted C_1 - C_6 alkyl or CF_3 , and R^{49} and R^{54} represent hydrogen;

 A_1 and A_2 are the same and represent -CH₂-; Q^1 , Q^2 , Q^3 , Q^4 and Q^5 each represent phosphorus;

5 M represents Fe;

n=1 and L_1 represents cyclopentadienyl; particularly unsubstituted cyclopentadienyl, and m=0.

10 (22) X¹, X², X³ and X⁴ independently represent congressyl, especially where X¹ to X⁴ represent the same congressyl group;

A₁ and A₂ are the same and represent -CH₂-;

 K^1 , D^1 and E^1 are the same and represent hydrogen or unsubstituted $C_1\text{-}C_6$ alkyl, particularly hydrogen;

 Q^1 and Q^2 both represent phosphorus;

M represents Fe;

n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=1

20 0.

15

- (23) X^1 , X^2 , X^3 and X^4 independently represent congressyl, especially where X^1 to X^4 represent the same congressyl group;
- 25 K^1 represents $-CH_2-Q^3\left(X^5\right)X^6$ wherein X^5 and X^6 independently represent congressyl, especially where X^3 to X^6 represent the same congressyl group;

 A_1 and A_2 are the same and represent $-CH_2-$;

 Q^{1} , Q^{2} and Q^{3} each represent phosphorus;

30 D^1 and E^1 are the same and represent hydrogen or unsubstituted $C_1\text{-}C_5$ alkyl, particularly hydrogen; M represents Fe;

n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.

5 (24) X^1 , X^2 , X^3 and X^4 independently represent congressyl, especially where X^1 to X^4 represent the same congressyl group;

 K^1 represents $-CH_2-Q^3\left(X^5\right)X^6$ wherein X^5 and X^6 independently represent congressyl, especially where

10 X1 to X4 represent the same congressyl group;

 A_1 and A_2 are the same and represent -CH₂-;

 Q^1 , Q^2 and Q^3 each represent phosphorus;

D1 and E1 together with the carbon atoms of the cyclopentadienyl ring to which they are attached

form an unsubstituted phenyl ring;

M represents Fe;

n = 1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and $m = 0\,.$

20

(25) X^1 , X^2 , X^3 and X^4 independently represent congressyl, especially where X^1 to X^4 represent the same congressyl group;

 A_1 and A_2 are the same and represent $-CH_2$ -;

25 Q¹ and Q² both represent phosphorus;

 K^1 represents hydrogen or unsubstituted C_1 - C_6 alkyl, particularly hydrogen;

D¹ and E¹ together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted whereal at

form an unsubstituted phenyl ring;

M represents Fe:

- n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.
- 5 (26) X^1 , X^2 , X^3 and X^4 independently represent congressyl; $\mathbf{x}^{\mathbf{5}}$ $-GH^3-O_3(X_2)X_6$ wherein represents $K^{\mathbf{l}}$ independently represent congressyl; χâ and \mathbf{x}^{7} represents -CH2-Q4(X7)X8 wherein D1 independently represents congressyl; and wherein represents -CH2-Q5(X9)X10 X9 10 especially independently represents congressyl, where X1 to X10 represent the same congressyl group; A_1 and A_2 are the same and represent -CH₂-; Q^1 , Q^2 , Q^3 , Q^4 and Q^5 each represent phosphorus; M represents Fe; 15
 - n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.
- adamantyl, independently represent and X3 x1 (27)20 especially where X^1 and X^3 represent same the adamantyl group; represents X^4 and $CR^4(R^5)(R^6)$ represents \mathbf{X}^2 $CR^{10}(R^{11})$ (R^{12}) wherein each of R^4 , R^5 , R^6 , R^{10} , R^{11} and C_1-C_5 alkyl represent independently 25 trifluoromethyl, particularly where each of R4 to R6 and R^{10} to R^{12} is identical, especially where each of R^4 to R^6 and R^{10} to R^{12} represents unsubstituted $C_1\!-\!C_6$ alkyl, particularly methyl;
 - A₁ and A₂ are the same and represent $-CH_2-$; K^1 , D^1 and E^1 are the same and represent hydrogen or unsubstituted C_1-C_6 alkyl, particularly hydrogen; Q^1 and Q^2 both represent phosphorus;

M represents Fe;

n=1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.

5

15

20

- (28) X^1 and X^3 independently represent adamantyl, especially where X^1 and X^3 represent the same adamantyl group;
- K^{t} represents $-CH_{2}-Q^{3}(X^{5})X^{6}$ wherein X^{5} represents adamantyl, especially where X^{1} , X^{3} and X^{5} represent the same adamantyl group;

 X^2 represents $CR^4(R^5)(R^6)$, X^4 represents $CR^{10}(R^{11})(R^{12})$, X^6 represents $CR^{16}(R^{17})(R^{18})$, wherein each of R^4 to R^6 , R^{10} to R^{12} and R^{16} to R^{18} independently represent unsubstituted C_1 - C_6 alkyl or trifluoromethyl, particularly where each of R^4 to R^6 , R^{10} to R^{12} , and R^{16} to R^{18} is identical, especially where each of R^4 to R^6 , R^{10} to R^{12} and R^{16} to R^{18} represents

unsubstituted C_1 - C_6 alkyl, particularly methyl; A_1 and A_2 are the same and represent $-CH_2$ -;

 Q^1 , Q^2 and Q^3 each represent phosphorus; D^1 , and E^1 are the same and represent hydrogen or unsubstituted C_1 - C_6 alkyl, particularly hydrogen;

M represents Fe;

- n = 1 and L_1 represents cyclopentadienyl, particularly unsubstituted cyclopentadienyl, and m=0.
- (29) X^1 and X^3 independently represent adamantyl, especially where X^1 and X^3 represent the same adamantyl group;

 K^2 represents $-CH_2-Q^3(X^5)X^6$ wherein X^5 represents adamantyl, especially where X^1 , X^3 and X^5 represent the same adamantyl group; X^2 represents $CR^4(R^5)(R^6)$, X^4 represents $CR^{10}(R^{11})(R^{12})$, X^6 represents $CR^{16}(\mathbb{R}^{17})$ (\mathbb{R}^{18}), wherein each of \mathbb{R}^4 to \mathbb{R}^6 , 5 R^{10} to R^{12} and R^{16} to R^{18} independently represent C_1-C_6 alkyl or trifluoromethyl, unsubstituted particularly where each of R4 to R6, R10 to R12, and R15 to R18 is identical, especially where each of R4 to R^6 , R^{10} to R^{12} and R^{16} to R^{18} represents 10 unsubstituted C1-C5 alkyl, particularly methyl; A_1 and A_2 are the same and represent -CH₂-; Q^1 , Q^2 and Q^3 each represent phosphorus; -D1 and E1 tegether - with the carbon atoms of the cyclopentadienyl ring to which they are attached 15 form an unsubstituted phenyl ring; M represents Fe; $\mathtt{L_1}$ represents cyclopentadienyl, and = particularly unsubstituted cyclopentadienyl, and m = 0. 20 \mathbf{x}^{3} independently represent adamantyl, and (30) $\mathbf{x_{r}}$ especially where X^1 and X^3 represent the same adamantyl group;

 $CR^4(R^5)(R^6)$ and X4 represents represents 25 $CR^{10}(R^{11})(R^{12})$ wherein each of R^4 , R^5 , R^6 , R^{10} , R^{11} and independently represent C1-C6 alkyl \mathbb{R}^{12} trifluoromethyl, particularly where each of \mathbb{R}^4 to \mathbb{R}^6 and R^{10} to R^{12} is identical, especially where each of R^4 to R^6 and R^{10} to R^{12} represents unsubstituted C_1-C_6 30 alkyl, particularly methyl; A_1 and A_2 are the same and represent -CH₂-; Q1 and Q2 both represent phosphorus;

10

15

25

K1 represents hydrogen or unsubstituted C1-C6 alkyl, particularly hydrogen; D1 and E1 together with the carbon atoms of the cyclopentadienyl ring to which they are attached form an unsubstituted phenyl ring; M represents Fe: cyclopentadienyl, represents and Ľ'n n particularly unsubstituted cyclopentadienyl, and m = Ο. Specific but non-limiting examples of bidentate ligands within this embodiment include the following: 1,2-bis-1,2-bis-(dimethylaminomethyl) ferrocene, (ditertbutylphosphinomethyl) ferrocene, 1-hydroxymethyl-2-1,2-bisdimethylaminomethylferrocene, 1-hydroxymethyl-(ditertbutylphosphinomethyl) ferrocene,

butylphosphinomethyl) ferrocene,
(dicyclopentylphosphinomethyl) ferrocene,

2,3-bis-(dimethylaminomethyl)ferrocene,

(ditertbutylphosphinomethyl) ferrocene, (dicyclohexylphosphinomethyl) ferrocene.

1,2-bis-1,2-bis(di-

1,2-bis-(di-(1,3,5,7-

1,2-bis-{di-iso-

1,2,3-tris-

1,2-bis-

1.2-bis-

(diethylphosphinomethyl) ferrocene, isopropylphosphinomethyl) ferrocene,

1,2-bis-

(dimethylphosphinomethyl) ferrocene, tetramethyl-6,9,10-trioxa-2-phospha-

adamantylmethyl))ferrocene,

1,2-bis-

1,2-

(dimethylaminomethyl) ferrocene-bismethyl iodide,

bis (dihydroxymethylphosphinomethyl) ferrocene, 1,2-

bis (diphosphinomethyl) ferrocene, 1,2-bis-a,a-(P-(2,2,6,6,-

30 tetramethylphosphinan-4-one))dimethylferrocene, and 1,2bis-(di-1,3,5,7-tetramethyl-6,9,10-trioxa-2-phosphaadamantylmethyl))benzene. Nevertheless, the skilled

person in the art would appreciate that other bidentate

TO @1633814444

ligands can be envisaged without departing from the scope of the invention.

According to a further aspect, the present invention provides a process for the carbonylation of an ethylenically unsaturated compound comprising contacting an ethylenically unsaturated compound with carbon monoxide and a hydroxyl group containing compound in the presence of a catalyst system as defined in the present invention.

Preferably, the process is a liquid phase continuous process comprising the step noted above. Nevertheless, although the process is preferably operated continuously, batch operation is possible.

suitably, the hydroxyl group containing compound includes 15 water or an organic molecule having a hydroxyl functional group. Preferably, the organic molecule having a hydroxyl functional group may be branched or linear, and comprises an alkanol, particularly a $C_1 - C_{30}$ alkanol, including aryl alkanols, which may be optionally substituted with one or more substituents selected from lower alkyl, aryl, Het, halo, cyano, nitro, QR^{19} , $QC(Q)R^{20}$, $C(Q)R^{21}$, $C(Q)QR^{22}$, $NR^{23}R^{24}$, $C(0)NR^{25}R^{26}$, $C(5)R^{25}R^{26}$, SR^{27} or $C(0)SR^{28}$ as defined Highly preferred alkanols are C1-C8 alkanols such as methanol, ethanol, propanol, iso-propanol, iso-butanol, 25 and chlorocapryl t-butyl alcohol, n-butanol, phenol alcohol. Although the monoalkanols are most preferred, poly-alkanols, preferably, selected from di-octa ols such as diols, triols, tetra-ols and sugars may also be Typically, such polyalkanols are selected from utilised. 2-ethanediol, 1,3-propanediol, glycerol, 2-(hydroxymethyl)-1,3-propanediol, 1,2,5 1,1,1 pentaerythritol, trihydroxyhexane,

10⁻/-ED⁻2554 10.64

5

15

LINULI

tri(hydroxymethyl)ethane, nannose, sorbase, galactose and other sugars. Preferred sugars include sucrose, fructose and glucose. Especially preferred alkanols are methanol and ethanol. The most preferred alkanol is methanol.

The amount of alcohol is not critical. Generally, amounts are used in excess of the amount of ethylenically unsaturated compound to be carbonylated. Thus the alcohol may serve as the reaction solvent as well, although, if desired, separate solvents may also be used.

It will be appreciated that the end product of the reaction is determined at least in part by the source of hydroxyl-group containing compound used. If water is used as the hydroxyl group containing compound then the end product is the corresponding carboxylic acid, whereas use of an alkanol produces the corresponding ester.

In the process according to the present invention, the carbon monoxide may be used in pure form or diluted with an inert gas such as nitrogen, carbon dioxide or a noble gas such as argon. Small amounts of hydrogen, typically less than 5% by volume, may also be present.

The ratio (volume/volume) of ethylenically unsaturated compound to hydroxyl group containing compound may vary between wide limits and suitably lies in the range of 1:0.1 to 1:10, preferably from between 2:1 to 1:2 and up to a large excess of hydroxyl group containing compounds when the latter is also the reaction solvent such as up to a 50:1 excess of hydroxyl group containing compounds.

The molar ratio of the ethylenically unsaturated compound to carbon monoxide is preferably in the range 1:1 to 100:1 more preferably greater than 1:1, even more preferably at least 3:1, especially from 3:1 to 50:1, and most preferably in the range from 3:1 to 15:1.

The amount of the catalyst of the invention used in the carbonylation process of the ethylenically unsaturated compound is not critical. Good results may be obtained when, preferably, the amount of Group VIB or VIIIB metal is in the range 10⁻⁷ to 10⁻¹ moles per mole of ethylenically unsaturated compound, more preferably, 10⁻⁶ to 10⁻² moles, most preferably 10⁻⁵ to 10⁻² moles per mole of ethylenically unsaturated compound. Preferably, the amount of bidentate compound of formula I or formula III to unsaturated compound is in the range 10⁻⁷ to 10⁻¹, more preferably, 10⁻⁶ to 10⁻², most preferably, 10⁻⁵ to 10⁻² moles per mole of ethylenically unsaturated compound.

Suitably, although non-essential to the invention, the 20 carbonylation of an ethylenically unsaturated compound as defined herein may be performed in one or more aprotic solvents. Suitable solvents include ketones, such as for example methylbutylketone; ethers, such as for example 25 anisole (methyl phenyl ether), 2,5,8-trioxanonane (diglyme), diethyl ether, dimethyl ether, tetrahydrofuran, diphenylether, diisopropylether and the dimethylether of di-ethylene-glycol; esters, such **45** for methylacetate, dimethyladipate methyl benzoate, dimethyl phthalate and butyrolactone; amides, such as for example 30 dimethylacetamide, N-methylpyrrolidone and formamide; sulfoxides and sulphones, such as for example dimethylsulphoxide, di-isopropylsulphone, sulfolane

(tetrahydrothiophene-2,2-dioxide), 2-methylsulfolane, diethyl sulphone, tetrahydrothiophene 1,1-dioxide and 2-methyl-4-ethylsulfolane; aromatic compounds, including halo variants of such compounds eg. benzene, toluene, ethyl benzene o-xylene, m-xylene, p-xylene, chlorobenzene, o-dichlorobenzene, m-dichlorobenzene: alkanes, including halo variants of such compounds eg, hexane, heptane, 2,2,3-trimethylpentane, methylene chloride and carbon tetrachloride; nitriles eg, benzonitrile and acetonitrile.

10

15

20

Very suitable are aprotic solvents having a dielectric constant that is below a value of 50, more preferably in the range of 3 to 8, at 298.15 K and 1 \times 10 5 Nm $^{-2}$. In the present context, the dielectric constant for a given solvent is used in its normal meaning of representing the ratio of the capacity of a condenser with that substance as dielectric to the capacity of the same condenser with a vacuum for dielectric. Values for the dielectric constants common organic liquids can be found in general reference books, such as the Handbook of Chemistry and Physics, 76th edition, edited by David R. Lide et al, and published by CRC press in 1995, and are usually quoted for a temperature of about 20°C or 25°C, i.e. about 293.15k or 298.15 K, and atmospheric pressure, i.e. about 1 x 105Nm-2, or can readily be converted to that temperature and pressure using the conversion factors quoted. literature data for a particular compound is available, the dielectric constant may be readily measured using established physico-chemical methods.

. 30

25

For example, the dielectric constant of anisole is 4.3 (at 294.2 K), of diethyl ether is 4.3 (at 293.2 K), of sulfolane is 43.4 (at 303.2 K), of methylpentanoate is 5.0

(at 293.2 K), of diphenylether is 3.7 (at 283.2 K), of dimethyladipate is 6.8 (at 293.2 K), of tetrahydrofuran is 7.5 (at 295.2 K), of methylnonanoate is 3.9 (at 293.2 K). A preferred solvent is anisole.

5

10

30

If the hydroxyl group containing compound is an alkanol, an aprotic solvent will be generated by the reaction as the ester carbonylation product of the ethylenically unsaturated compound, carbon monoxide and the alkanol is an aprotic solvent.

The process may be carried out in an excess of aprotic solvent, i.e. at a ratio (v/v) of aprotic solvent to hydroxyl group containing compound of at least 1:1.

15 Preferably, this ratio ranges from 1:1 to 10:1 and more preferably from 1:1 to 5:1. Most preferably the ratio

Despite the aforegoing it is preferred that the reaction 20 is carried out in the absence of any external added aprotic solvent ie. an aprotic solvent not generated by the reaction itself.

(v/v) ranges from 1.5:1 to 3:1.

The catalyst compounds of the present invention may act as a "heterogeneous" catalyst or a "homogeneous" catalyst.

By the term "homogeneous" catalyst we mean a catalyst, i.e. a compound of the invention, which is not supported but is simply admixed or formed in-situ with the reactants of the carbonylation reaction (e.g. the ethylenically unsaturated compound, the hydroxyl containing compound and carbon monoxide), preferably in a suitable solvent as described herein.

By the term "heterogeneous" catalyst we mean a catalyst, i.e. the compound of the invention, which is carried on a support.

5

10

15

Thus according to a further aspect, the present invention provides a process for the carbonylation of ethylenically unsaturated compounds as defined herein wherein the process is carried out with the catalyst comprising a support, preferably an insoluble support.

Preferably, the support comprises a polymer such as a polyclefin, polystyrene or polystyrene copolymer such as a divinylbenzene copolymer or other suitable polymers or copolymers known to those skilled in the art; a silicon derivative such as a functionalised silica, a silicone or a silicone rubber; or other porous particulate material such as for example inorganic oxides and inorganic chlorides.

20

25

Preferably the support material is porous silica which has a surface area in the range of from 10 to 700 m²/g, a total pore volume in the range of from 0.1 to 4.0 cc/g and an average particle size in the range of from 10 to 500 µm. More preferably, the surface area is in the range of from 50 to 500 m²/g, the pore volume is in the range of from 0.5 to 2.5 cc/g and the average particle size is in the range of from 20 to 200 µm. Most desirably the surface area is in the range of from 100 to 400 m²/g, the pore volume is in the range of from 0.8 to 3.0 cc/g and the average particle size is in the range of from 30 to 100 µm. The average pore size of typical porous support materials is in the range of from 10 to 1000 Å.

Preferably, a support material is used that has an average pore diameter of from 50 to 500 Å, and most desirably from 75 to 350 Å. It may be particularly desirable to dehydrate the silica at a temperature of from 100°C to 800°C anywhere from 3 to 24 hours.

Suitably, the support may be flexible or a rigid support, the insoluble support is coated and/or impregnated with compounds of the process of the invention by techniques well known to those skilled in the art.

Alternatively, the compounds of the process of invention are fixed to the surface of an insoluble support, optionally via a covalent bond, and 15 arrangement optionally includes a bifunctional spacer molecule to space the compound from the insoluble support.

The compounds of the invention may be fixed to the surface of the insoluble support by promoting reaction of a 20 functional group present in the compound of formula I or III, for example a substituent K, D, Z and E (or K^1 , D^1 and E1) of the aryl moiety, with a complimentary reactive group present on or previously inserted into the support. The combination of the reactive group of the support with a complimentary substituent of the compound of invention provides a heterogeneous catalyst where the compound of the invention and the support are linked via a linkage such as an ether, ester, amide, amine, urea, keto group.

30

25

10

The choice of reaction conditions to link a compound of the process of the present invention to the support depend upon the ethylenically unsaturated compound and the groups

of the support. For example, reagents such as carbodimides, 1,1'-carbonyldimidazole, and processes such as the use of mixed anhydrides, reductive amination may be employed.

5

According to a further aspect, the present invention provides the use of the process of any aspect of the invention wherein the catalyst is attached to a support.

- 10 Conveniently, the process of the invention may be carried out by dissolving the Group VIB or VIIIB metal or compound thereof as defined herein in a suitable solvent such as one of the hydroxyl group containing compounds or aprotic solvents previously described (a particularly preferred solvent would be the ester or acid product of the specific carbonylation reaction e.g. Methyl propionate for ethylene carbonylation) and subsequently admixing with a compound of formula I or III as defined herein and an acid.
- The carbon monoxide may be used in the presence of other gases which are inert in the reaction. Examples of such gases include hydrogen, nitrogen, carbon dioxide and the noble gases such as argon.
- Suitable Group VIB or VIIIB metals or a compound thereof which may be combined with a compound of formula I or III include cobalt, nickel, palladium, rhodium and platinum. Preferably, the Group VIIIB metal is palladium or a compound thereof. Suitable compounds of such Group VIB or VIIIB metals include salts of such metals with, or compounds comprising weakly coordinated anions derived from, nitric acid; sulphuric acid; lower alkanoic (up to C12) acids such as acetic acid and propionic acid;

30

72

sulphonic acids such methane sulphonic às acid, chlorosulphonic acid, fluorosulphonic acid, trifluoromethane sulphonic acid, benzene sulphonic acid, naphthalene sulphonic acid, toluene sulphonic acid, e.g. p-toluene sulphonic acid, t-butyl sulphonic acid, and 2hydroxypropane sulphonic acid; sulphonated ion exchange resing: perhalic acid such perchloric acid; 25 halogenated carboxylic acids such as trichloroacetic acid and trifluoroacetic acid; orthophosphoric acid; phosphonic 10 acids such as benzenephosphonic acid; and acids derived from interactions between Lewis acids and Broensted acids. Other sources which may provide suitable anions include the optionally halogenated tetraphenyl borate derivatives, perfluorotetraphenyl borate. Additionally, 15 valent palladium complexes particularly those with labile ligands, e.g. triphenylphosphine or alkenes as dibenzylideneacetone or styrene or tri(dibenzylideneacetone)dipalladium may be used. Nevertheless, an acid is present in the catalyst system as set out hereinbefore, even if other sources of anion such 20 as those noted above are also present.

Thus, the acid is selected from an acid having a pKa measured in aqueous solution at 18°C of less than 4, more preferably less than 3, most preferably less than 2. Suitable acids include the acids listed Preferably, the acid is not a carboxylic acid, preferably the acid is either a sulphonic acid, or some other non-carboxylic acid such as those selected from the list consisting of perchloric acid, phosphoric acid. methyl phosphonic acid, sulphuric acid, and sulphonic acids, even more preferably a sulphonic acid or other noncarboxylic acid (selected from the list above) having a

pKa measured in aqueous solution at 18°C of less than 2, yet even more preferably a sulphonic acid having a pKa measured in aqueous solution at 18°C of less than 2, still the acid is selected from the list more preferably following sulphonic acids: the consisting of trifluoromethanesulphonic acid, acid, methanesulphonic tert-butanesulphonic acid, p-toluenesulphonic hydroxypropane-2-sulphonic acid. and 2,4,6trimethylbenzenesulphonic acid, most preferably the acid is methanesulphonic acid.

As mentioned, the catalyst system of the present invention may be used homogeneously or heterogeneously. Preferably, the catalyst system is used homogeneously.

15

10

The catalyst system of the present invention is preferably constituted in the liquid phase which may be formed by one or more of the reactants or by the use of a suitable solvent.

20

The molar ratio of the amount of ethylenically unsaturated compound used in the reaction to the amount of hydroxyl providing compound is not critical and may vary between wide limits, e.g. from 0.001:1 to 100:1 mol/mol.

25

30

The product of the carbonylation reaction using the ligand of the invention may be separated from the other components by any suitable means. However, it is an advantage of the present process that significantly fewer by-products are formed thereby reducing the need for further purification after the initial separation of the product as may be evidenced by the generally significantly higher selectivity. A further advantage is that the other

30

components which contain the catalyst system which may be recycled and/or reused in further reactions with minimal supplementation of fresh catalyst.

- 5 Preferably, the carbonylation is carried out at a temperature of between -10 to 150°C, more preferably 0°C to 140°C, even more preferably 15°C to 140°C, most preferably 20°C to 120°C. An especially preferred temperature is one chosen between 80°C to 120°C.
- 10 Advantageously, the carbonylation can be carried out at moderate temperatures, it is particularly advantageous to be able to carry out the reaction at room temperature (20°C) .
- Preferably, when operating a low temperature carbonylation, the carbonylation is carried out between 30°C to 49°C, more preferably, -10°C to 45°C, still more preferably 0°C to 45°C, even more preferably 10°C to 45°C, most preferably 15°C to 45°C. Especially preferred is a range of 15 to 35°C.

Preferably, the carbonylation is carried out at a CO partial pressure of between $0.80 \times 10^5 \text{ N.m}^{-2}$ -90 x 10^5 N.m^{-2} , more preferably 1 x 10^5 N.m^{-2} -65 x 10^5 N.m^{-2} , most preferably 1-30 x 10^5 N.m^{-2} . Especially preferred is a CO partial pressure of 5 to 20 x 10^5 N.m^{-2} .

Preferably, a low pressure carbonylation is also envisaged. Preferably, when operating a low pressure carbonylation the carbonylation is carried out at a CO partial pressure of between 0.1 to 5 x 10^5N.m^{-2} , more preferably 0.2 to 2 x 10^5N.m^{-2} , most preferably 0.5 to 1.5 x 10^5N.m^{-2} .

The ethylenically unsaturated compounds may be substituted or non-substituted with groups as defined above for the "aryl" group above. Particularly suitable substituents 5 include alkyl and aryl groups as well as groups containing heteroatoms such as halides, sulphur, phosphorus, oxygen and nitrogen. Examples of substituents include chloride, browide, iodide and hydroxy, alkoxy, carboxy, amido, nitro, cyano, thiol or thioalkoxy groups. Suitable include ethylenically unsaturated compounds propene, hexene, vinyl compounds such as vinyl acetates, heptene, octene, nonene, decene, undecene, dodecene, etc up to C_{30} , i.e. having from 2 to 30 carbon atoms, which may be linear or branched, cyclic or uncyclic or part cyclic and in which the double bond may take any suitable position in the carbon chain and which includes all stereisomers thereof.

Moreover, the unsaturated compound may have one or more unsaturated bonds and therefore, for example, the range of ethylenically unsaturated compounds extends to dienes. The unsaturated bond(s) may be internal or terminal, the catalyst system of the invention being particularly advantageous in the conversion of internal olefins.

25

30

10

15

Particularly preferred are olefine having from 2 to 22 carbon atoms per molecule, such as ethene, propene, 1butene, 2-butene, isobutene, pentenes, hexenes, octenes, oct-2-ene, oct-3-ene, oct-4-ene. decenes and dodecenes, triisobutylene, tripropylene, internal olefins, and internal C15-C18 olefins, 1,5-cyclooctadiene, cyclododecene, methyl pentenoate and pentene nitriles, e.g. pent-2-ene nitrile.

The ethylenically unsaturated compound is preferably an alkene having 1 to 3 carbon-carbon double bonds per molecule. Non-limiting examples of suitable dienes include the following: 1,3-butadiene, 2-methyl-1,3-butadiene, 1,5-cyclooctadiene, 1,3-cyclohexadiene, 2,4-heptadiene, 1,3-pentadiene, 1,3-hexadiene, particularly 1,3-butadiene.

Another preferred category of unsaturated compounds consists of unsaturated esters of carboxylic acids and esters of unsaturated carboxylic acids. For example, the starting material may be a vinyl ester of a carboxylic acid such as acetic acid or propanoic acid, or it may be an alkyl ester of an unsaturated acid, such as the methyl or ethyl ester of acrylic acid or methacrylic acid.

A further preferred category of unsaturated compounds consists of cycloalkadienes, which will ordinarily refuse carbonylation. For example, the starting material may be dicyclopentadiene or norbornadiene, to give diesters, diamides: or diacids, etc., which may find subsequent use as monomers in polymerisation reactions.

The use of stabilising compounds with the catalyst system may also be beneficial in improving recovery of metal which has been lost from the catalyst system. When the catalyst system is utilized in a liquid reaction medium such stabilizing compounds may assist recovery of the Group VI or VIIIB metal.

Preferably, therefore, the catalyst system includes in a liquid reaction medium a polymeric dispersant dissolved in

a liquid carrier, said polymeric dispersant being capable of stabilising a colloidal suspension of particles of the Group VI or VIIIB metal or metal compound of the catalyst system within the liquid carrier.

5

10

The liquid reaction medium may be a solvent for the reaction or may comprise one or more of the reactants or reaction products themselves. The reactants and reaction products in liquid form may be miscible with or dissolved in a solvent or liquid diluent.

The polymeric dispersant is soluble in the liquid reaction medium, but should not significantly increase the viscosity of the reaction medium in a way which would be detrimental to reaction kinetics or heat transfer. The solubility of the dispersant in the liquid medium under the reaction conditions of temperature and pressure should not be so great as to deter significantly the adsorption of the dispersant molecules onto the metal particles.

20

25

30

The polymeric dispersant is capable of stabilising a colloidal suspension of particles of said Group VI or VIIIB metal or metal compound within the liquid reaction medium such that the metal particles formed as a result of catalyst degradation are held in suspension in the liquid reaction medium and are discharged from the reactor along with the liquid for reclamation and optionally for re-use in making further quantities of catalyst. The metal particles are normally of colloidal dimensions, e.g. in the range 5 - 100 nm average particle size although larger particles may form in some cases. Portions of the polymeric dispersant are adsorbed onto the surface of the metal particles whilst the remainder of the dispersant

76

molecules remain at least partially solvated by the liquid reaction medium and in this way the dispersed Group VI or VIIIB metal particles are stabilised against settling on the walls of the reactor or in reactor dead spaces and against forming agglomerates of metal particles which may grow by collision of particles and eventually coagulate. Some agglomeration of particles may occur even in the presence of a suitable dispersant but when the dispersant concentration type and is optimised then such agglomeration should be at a relatively low level and the agglomerates may form only loosely so that they may be broken up and the particles redispersed by agitation.

The polymeric dispersant may include homopolymers or copolymers including polymers such as graft copolymers and star polymers.

Preferably, the polymeric dispersant has sufficiently acidic or basic functionality to substantially stabilise the colloidal suspension of said Group VI or VIIIB metal or metal compound.

By substantially stabilise is meant that the precipitation of the Group VI or VIIIB metal from the solution phase is substantially avoided.

Particularly preferred dispersants for this purpose include acidic or basic polymers including carboxylic acids, sulphonic acids, amines and amides such polyacrylates or heterocycle, particularly nitrogen heterocycle. substituted polyvinyl polymers such polyvinyl pyrrolidone or copolymers of the aforesaid.

Examples of such polymeric dispersants may be selected polyvinylpyrrolidone, polyacrylamide, polyacrylonitrile, polyethylenimine, polyglycine, polyacrylic acid, polymethacrylic acid, poly(3hydroxybutyricacid), poly-L-leucine, poly-L-methionine, poly-L-proline, poly-L-serine, poly-L-tyrosine, poly(vinylbenzenesulphonic acid) and poly(vinylsulphonic acid).

- 10 Preferably, the polymeric dispersant incorporates acidic or basic moieties either pendant or within the polymer backbone. Preferably, the acidic moieties have a dissociation constant (pK₃) of less than 6.0, more preferably, less than 5.0, most preferably less than 4.5.

 15 Preferably, the basic moieties have a base dissociation constant (pK_b) being of less than 6.0, more preferably less than 5.0 and most preferably less than 4.5, pK_a and pK_b being measured in dilute aqueous solution at 25°C.
- Suitable polymeric dispersants, in addition to being 20 soluble in the reaction medium at reaction conditions, contain at least one acidic or basic moiety, either within the polymer backbone or as a pendant group. We have found that polymers incorporating acid and amide moieties such as polyvinylpyrollidone (PVP) and polyacrylates such as 25 polyacrylic acid (PAA) are particularly suitable. The molecular weight of the polymer which is suitable for use in the invention depends upon the nature of the reaction medium and the solubility of the polymer therein. We have 30 found that normally the average molecular weight is less than 100,000. Preferably, the average molecular weight is in the range 1,000 - 200,000, more preferably, 5,000 -100,000, most preferably, 10,000 - 40,000 e.g. Mw is

preferably in the range 10,000 - 80,000, more preferably 20,000 - 60,000 when PVP is used and of the order of 1,000 - 10,000 in the case of PAA.

5 The effective concentration of the dispersant within the reaction medium should be determined for each reaction/catalyst system which is to be used.

The dispersed Group VI or VIIIB metal may be recovered from the liquid stream removed from the reactor e.g. by filtration and then either disposed of or processed for re-use as a catalyst or other applications. In a continuous process the liquid stream may be circulated through an external heat-exchanger and in such cases it may be convenient to locate filters for the palladium particles in these circulation apparatus.

Preferably, the polymer: metal mass ratio in g/g is between 1:1 and 1000:1, more preferably, between 1:1 and 400:1, 20 most preferably, between 1:1 and 200:1. Preferably, the polymer: metal mass ratio in g/g is up to 1000, more preferably, up to 400, most preferably, up to 200.

According to a further aspect there is provided a reaction
25 medium comprising one or more reactants, and a catalyst
system comprising, or obtainable by combining, at least a
Group VIB or VIIIB metal or metal compound, a bidentate
phosphine, arsine, or stibine ligand, and an acid, as
defined herein, wherein said ligand is present in at least
30 a 2:1 molar excess compared to said metal or said metal in
said metal compound, and that said acid is present in at
least a 2:1 molar excess compared to said ligand.

medium is Preferably, said reaction liquid-phase preferably liquid-phase reaction medium, more a continuous-system reaction system.

Preferably, within said reaction medium, the amount of free acid present in the medium, that is acid which is not -directly-combined with the phosphine ligand, is greater than 500ppm, more preferably greater than 1000ppm, most preferably greater than 2000ppm.

According to a further aspect the invention provides a for preparing the catalyst 10 systems invention comprising combining components a), b) and c) as defined herein, preferably in the aforementioned ratios.

According to a yet further aspect the present invention provides the use of a system comprising, or obtainable by combining:

- a metal of Group VIB or Group VIIIB or a compound thereof,
- a bidentate phosphine, arsine, or stibine ligand, preferably a bidentate phosphine ligand, and
- 20 an acid,

wherein said ligand is present in at least a 2:1 molar excess compared to said metal or said metal in said metal compound, and that said acid is present in at least a 2:1 molar excess compared to said ligand, as a catalyst in the carbonylation of an ethylenically unsaturated compound, preferably the liquid-phase carbonylation an ethylenically unsaturated compound, more preferably the liquid-phase continuous-system carbonylation of an ethylenically unsaturated compound.

30

25

15

For the avoidance of any doubt, each and every feature described hereinbefore is equally applicable to any or all of the various aspects of the present invention as set out

supra., unless such features are incompatible with the particular aspect or are mutually exclusive.

All documents mentioned herein are incorporated by reference thereto.

The following examples further illustrate the present invention. These examples are to be viewed as being illustrative of specific materials falling within the broader disclosure presented above and are not to be viewed as limiting the broader disclosure in any way.

Example 1

Preparation of 1,2 bis (diadamantylphosphinomethyl) benzene

15

1,2 bis(diadamantylphosphinomethyl) benzene

(Method 1)

The preparation of this ligand was carried out as follows.

1.1 Preparation of (1-Ad)₂P(0)Cl

Phosphorous trichloride (83 cm3, 0.98 mol) was added rapidly via cannula to a combination of aluminium chloride (25.0 g, 0.19 mol) and adamantane (27.2 g, 0.20 mol) affording a tan suspension. The reaction was heated to reflux. After 10 mins, a yellow-orange suspension was formed. The reaction was refluxed for a total of 6 h. The 10 excess PCl3 was removed by distillation at atmospheric pressure (BP 75 °C). On cooling to ambient temperature, an orange solid was formed. Chloroform (250 cm3) was added yielding an orange suspension, which was cooled to 0 °C. Water (150 cm3) was added slowly: initially the suspension viscosity increased, but on full addition of water the 15 viscosity lessened. From this point the reaction was no longer kept under an atmosphere of Ar. The suspension was Buchner filtered to remove the yellow-orange solid impurity. The filtrate consisted of a two phase system. 20 The lower phase was separated using a separating funnel, dried over MgSO4 and Buchner filtered. The volatiles were removed via rotary evaporation, drying finally in-vacuo, affording an off-white powder. Yield 35.0 g, 99 %. 31p NMR: $\overline{o} = 85$ ppm, 99 % pure. FW = 352.85.

25

1.2 Preparation of (1-Ad)2PH

LiAlH₂ (2.54 g, 67.0 mmol) was added over 90 minutes to a chilled (-10 °C) solution of (1-Ad)₂P(O)Cl (10.00 g, 28.3 mmol) in THF. (120 cm³). The reaction was allowed to warm to ambient temperature then stirred for 20 h. The grey suspension was cooled to -10 °C. HCl (aq., 5 cm³ c, HCl in

(initially very slowly due to exotherm of reaction), yielding a two phase system, with some solid material in the lower phase. Further HCl (~ 5 cm³ c. HCl) was added to improve the separation of the layers. The upper phase was removed via flat ended cannula, dried over MgSO₄ and filtered via cannula. The volatiles were removed in-vacuo affording the product as a white powder, isolated in the glovebox. Yield 6.00 g, 70 %. ³¹p NMR: 5= 17 ppm, 100 % pure. FW = 302.44.

1.3 Preparation of (1-Ad)₂PCl

A solution of Ad₂PH (10.5 g, 34.7 mmol) and DBU $(6.12 \text{ cm}^3,$ 40.9 mmol) in toluene (250 cm³) was chilled to -10 °C. 15 Phosgene solution (30.0 cm3, 56.7 mmol, was added slowly via cannula, transferring via a measuring cylinder. This highly viscous pale vellow suspension. afforded а Additional toluene (100 cm3) was added via cannula to lessen the viscosity and ease the stirring. The reaction 20 was filtered via cannula affording a yellow filtrate. The residue was washed with additional toluene (2 \times 100 cm³) and the washings combined with the original filtrate. The volatiles were removed in-vacuo affording a pale yellow solid, which was washed with pentane (2 imes 30 cm 3 , washings 25 practically colourless). The product was dried in-vacuo and isolated in the glovebox as a lemon yellow powder. Yield 7.84 g, 67 %. 31 P NMR: δ = 139 ppm, 99+ % pure. FW = 336.88.

30

10

1.4 Preparation of adamantylphosphinomethyl)benzene

1,2-bis(di-1-

1.4.1 Preparation of DI-SODIO-ORTHO-XYLENE (DISOD)

BuⁿLi (2.5 M in hexanes, 11.28 cm³, 28.2 mmol) was added dropwise via syringe over 15 minutes to a stirred suspension of NaOBu^t (crushed, 2.71 g, 28.2 mmol), oxylene (1.15 cm³, 9.4 mmol) and N,N,N',N' - tetramethyl ethylene diamine (TMEDA) (4.26 cm³, 28.2 mmol) in heptane (100 cm³). The reaction was heated at 60 °C for 2 h, then allowed to cool / settle, affording a bright orange solid (DISOD) and pale yellow solution. The solution was removed via cannula filtration and the solid washed with additional heptane (50 cm³) and dried in-vacuo. 90 % yield assumed, 8.47 mmol.

15

10

1.4.2 Reaction of DI-SODIO-ORTHO-XYLENE with 2 equiv (1-Ad) PCl

A suspension of DISOD (8.47 mmol) in Et₂O (100 cm³) was prepared at -78 °C. A suspension of AdaPCl (5.70 g, 16.9 20 mmol) in Et₂O (120 cm³) was stirred rapidly at -78 °C and added via wide-bore cannula to the DISOD suspension. The reaction was allowed to warm to ambient temperature and stirred for 18 h, affording a pale yellow turbid solution. Water (degassed, 100 cm 3) added via cannula affording a 25 two phase system, with a great deal of white solid present (product) due to the low solubility of this material. The upper phase (Et2O) was removed via cannula. The solid in the aqueous phase was extracted using dichloromethane (200 30 cm3), forming two clear phases. The lower phase (CH2Cl2) was removed via cannula and combined with the original Et2O phase. The volatiles were removed in-vacuo yielding a

slightly sticky solid. The solid was washed with pentane (200 cm^3) with attrition being performed, the washings being removed via cannula filtration. The white solid was dried *in-vacuo* and isolated in the glovebox as a friable white powder. Yield 3.5 g, 59 %. FW = 707.01.

³¹p $\{^1H\}NMR$ data: - δ 24 ppm.

 $\frac{1}{H}$ NMR data:- (400 MHz, CDCl₃, 298 K) δ 7.59-7.50 (m, 2H, 10 Ar-H), 7.09-6,99 (m, 2H, Ar-H), 3.01 (d, 4H, $^{2}J_{PH}$ = 3.2 Hz, CH₂), 2.07-1.57 (m, 60H, C₁₀H₁₅) ppm.

 13 C 1 H 1 NMR data: - (100 MHz, CDCl₃, 298 K) δ 139.4 (dd, J_{PC} = 10.7 Hz, J_{PC} = 2.3 Hz, Ar-C), 131.0 (d, J_{PC} = 16.8 Hz, Ar-C), 125.0 (g, Ar-C), 41.1 (d, 2 J_{PC} = 10.7 Hz, Ad-C²), 37.2 (g, Ad-C⁴), 36.9 (d, 1 J_{PC} = 22.9 Hz, Ad-C¹), 28.8 (d, 3 J_{PC} = 7.6 Hz, Ad-C³), 22.0 (dd, 1 J_{PC} = 22.9 Hz, 4 J_{FC} = 3.1 Hz, CH₂).

20 Example 2

5

Preparation of 1,2 bis(diadamantylphosphinomethyl) benzene (method 2)

- 2.1 Di-1-adamantyl phosphinic chloride was prepared in accordance with the method of Example 1.1.
 - 2.2 Di-1-adamantyl phosphine was prepared in accordance with the method of Example 1.2.
- 2.3 (Di-1-adamantyl phosphine) tribydro boron. Borane (THF) adduct (10 cm3, 10mmol) was added to stirred solution of di-1-adamantyl phosphine (1.36g, 4.5mmol) in

87

THF $(30\,\mathrm{cm}^3)$. Stirring for a further 5hrs afforded a slightly turbid solution. The volatiles were then removed in-vacuo to yield the product as a pure white solid. Yield: 1.39g, 98%, 99% pure. FW: 315.25. ³¹P NMR: δ 41ppm (d, J_{PB} 64 Hz).

2.4 Synthesis οĒ 1,2 bis (d1-1adamantylphosphor(borane)methyl) benzene via deprotonation with secBuLi and reaction with an dichloro o-xylene. 10 stirred, cooled (-78°) THF solution (60cm3) of di-1adamantyl phosphine trihydroboron (5g, 15.8mmol), slowly added (via syringe) secBuLi (12.3cm3, 16.6mmol), upon full addition the solution had a noticeable yellow colouration. The solution was stirred for 30 minutes at -78° and then allowed to warm to room temperature and stir 15 for a further 120 minutes. The solution was then cooled to -78° and a THF solution (20cm3) of $\alpha\alpha$ dichloro o-xylene was added via cannula. The solution was then allowed to warm to room temperature and stirred for 15 hrs. The volatiles where then removed in-vacuo. No further work up 20 was required as LiCl and excess organics are removed during the deprotection procedure, Yield: 100% 85% pure.

³¹P $\{^{1}H\}$ NMR (CDCl₃,298K) δ (d, br) 41 ppm.

¹¹B $\{^1H\}$ NMR δ -43 ppm (d. J_{BP} 44 Hz)

2.5 Synthesis of 1,2-bis(di-30 adamantylphosphinomethyl)benzene via deprotection of 1,2 bis (di-adamantylphosphor(boxane)methyl) benzene with HBF4.0(ME)2.

Tetrafluoroboric acid dimethyl ether complex (5 12.5mmols, 1.5cm³) was equivalents, added slowly via syringe to a cooled (0°c) stirred solution of 1,2 bis (diadamantylphosphor (borane) methyl benzene (70 dichloromethane). The solution was stirred at 0°c for 1 hour and then allowed to warm to ambient temperature and stir for a further 12 hours. The reaction mixture was then added to a cooled (0°c) saturated solution (degassed) NaHCO3 solution (5* excess NaHCO3) and stirred vigorously 10 for 50 minutes. The organic phase was then extracted with 2*30 cm³ portions of diethyl ether, and added to the DCM extract. The organic layers were then washed with 2 x 30 cm3 portions of degassed water and dried over MgSO4. The volatiles were then removed in-vacuo.

 ^{31}P { ^{2}H } NMR:8 26.4 ppm (s).


 H^{1} NMR (CDCl₃, 298K) δ 7.54 ppm (q, Ar-H, J_{HH} 3.4 Hz), 7.0 20 $ppm (q, Ar-H, J_{HH} 3.4 Hz), 3.0 ppm (d, br CH₂) 1.6-2.1 ppm$ (m, br C10H15).

Example 3

15

Preparation of (di-3,5-1,2 bis

25 dimethyladamantylphosphinomethyl) benzene (method 2)



1,2-bis(di-1-(3,5-dimethyl-adamantyl) phosphinomethyl) benzene

3.1 Di-1-(3,5-dimethyladamantyl) phosphinic chloride was prepared in accordance with the method of Example 2.1 except using 1,3 dimethyladamantane 21.7g (0.132 mol) instead of adamantane, and AlCl₃ (18.5gg, 0.14 mol). Yield 23.5g FW: 409.08.. ³¹P NMR: δ: 87ppm (s).

- 3.2 Di-1-(3,5-dimethylademantyl) phosphine was prepared as per Example 2.2 above except using 25.0 g Di-1-(3,5-dimethylademantyl) phosphinic chloride instead of di-1-adamantyl phosphonic chloride Yield 15.7 g FW: 358.58..

 31p NMR: 8: 15.7ppm (s).
- 15 3.3 Di-1-(3,5-dimethyladamantyl) phosphine} trihydro boron was prepared as per Example 2.3 above except using 10.0 g Di-1-(3,5-dimethyladamantyl) phosphine instead of di-1-adamantyl phosphine. Yield 9.5 g ³¹P NMR; δ: 40.5ppm (br).


5

- 3.4 Synthesis of 1.2 bis (di-3,5-dimethyladamantyl (borane)methyl) benzene via deprotonation with secBuLi and reaction with an dichloro o-xylene was prepared as per Example 2.4 above except using equimolar amounts of di-3,5-dimethyl adamantyl phosphine trihydroboron instead of di-l-adamantyl phosphine trihydroboron.
- 3.5 Synthesis οf 1,2 bis (di-3,5dimethyladamantylphosphinomethyl) benzene via deprotection 10 1,2 bis (di-3,5-dimethyladamantyl phosphor(borane)methyl) benzene with HBF4'O (ME) 2 prepared as per 1,2 bis (di-1-adamantylphosphinomethyl) benzene (Example 2.5) above except by using equimolar of amounts bis (di-3,5~
- dimethyadamantylphosphor(borane)methyl) benzene instead of
 1,2 bis(di-adamantylphosphor(borane)methyl) benzene.

Example 4

Preparation of 1,2 bis (di-5-tert-

20 <u>butyladamantylphosphinomethyl</u>) benzene (method 2)



1,2-bis(di-1-(5-tert-butyl-adamantyl) phosphinomethyl) benzene

- 4.1 Di-1-(5-text-butyladamantyl) phosphinic chloride was
 prepared as per Di-1-adamantyl phosphinic chloride above

 5 except using tert-butyladamantane 25.37g (0.132 mol)
 instead of adamantane, and AlCl₂ (18.5gg, 0.14 mol).
 Yield 22.6g FW: 464.98... ³¹P NMR: δ: 87ppm (s).
- 4.2.1 Di-1-(5-tert-butyladamantyl) phosphine was
 prepared as per Di-1-adamantyl phosphine above except
 using 13.5 g Di-1-(5-tert-butyladamantyl) phosphinic
 chloride instead of di-1-adamantyl phosphinic chloride.
 Yield 9.4 g FW: 414.48.. ³¹P NMR: δ: 18.62ppm (s).
- 15 4.2.2 Di-1-(5-tert-butyladamantyl) phosphine) trihydro boron was prepared as per Di-1-adamantyl phosphine above except using 10.0 g Di-1-(5-tert-butyladamantyl) phosphine

instead of di-1-adamantyl phosphine. Yield 9.5 g ^{31}P NMR: δ : 41.6ppm (br).

- (di-5-tert-4.2.3 Synthesia ο£ bis 1,2 butyladamantylphosphor(borane)methyl) benzene via deprotonation with 800 Bulli and reaction with ac dichloro oxylene was prepared as per 1,2 bis (di-1adamantylphosphor (borane) methyl) benzene above except using equimolar amounts of di-l-(5-tert-butyladamantyl) 10 phosphine trihydroboron instead of di-1-adamantyl phosphine trihydroboron.
- 4.3 Synthesis of 1.2 bis (di-5-tertbutyladamantylphosphinomethyl) benzene via deprotection of 15 1,2 bis (di-4-tert-butyladamantyl phosphor(borane)methyl) benzene with HBF4 O(ME)2 was prepared as per 1,2 bis (di-1adamantylphosphinomethyl) benzene above except 1,2 bis(di-5-tert-butyladamantylphosphor(borane)methyl) used instead σf 1,2 bis(di-20 adamantylphosphor(borane)methyl) benzene equimolar in amounts.

Example 5

30

Preparation of 1,2 bis(1-adamantyl tert-butylphosphinomethyl) benzene (method 2)

- 5.1. 1-adamantylphosphonic acid dichloride. This compound was synthesised according to the method of Olah et al (J. Org. Chem. 1990, 55, 1224-1227).
- 5.2 1-adamantyl phosphine. LiAlH, (3.5g, 74mmol) was added over 2 hrs to a cooled solution (0°C) of 1-

adamantylphosphonic acid dichloride (15g, 59 mmol) in THF (250 cm³). The reaction was then allowed to warm to ambient temperature and was stirred for 20 hrs. The grey suspension was then cooled (0°C) and HCl (75 cm3, 1M) was slowly added via syringe, to afford a two phase system with some solid present in the lower phase. Concentrated HCl (8cm³, 11M) was then added to improve the separation of the two layers. The (upper) THF phase was removed via cannula and dried over magnesium sulphate. After filtration via cannula, the volatiles were removed invacuo to afford the product.

5.3 (1-adamantyl-tert-butyl_phosphine) trihydro nBuLi (20 cm3, 32 mmol 1.6M soln) was added over 1 hour to a cooled solution of 1-adamantyl phosphine (5.0g 30 mmol) 15 in THF (100 cm³). The solution was allowed to warm to room temperature and stirred for a further 2 hours. The was recooled to 0°C and tert-butylchloride (2.78g, 30 mmol) was added and stirring continued for a further 16 hours at room temperature. 20 The material was isolated as the borane adduct by addition of Borane (THF) adduct (30 ÇM³, 30mmql) followed by removal The material was isolated as a white solid which was a mixture of isomers.

25

lo


5.4 Synthesis of 1,2 bis (1-adamantyl-tert-butyl phosphor (borane)methyl) benzene via deprotonation with sec Buli and reaction with an dichloro o-xylene. The synthesis was carried out as per 1,2 bis {di-1adamantylphosphor(borane)methyl) QΕ benzene above except equimolar amounts of l-adamantyl-tertbutyl (phosphine) trihydroboron were used instead of the di-1-adamantyl phosphine trihydroboron.

(1-adamantyl-tertbis 1,2 œΞ 5.5 Synthesis butylphosphinomethyl) benzene via deprotection of 1.2 bis (1-adamantyl-tert-butyl phosphor(borane)methyl) (dibis per 1,2 HBF4.0 (ME) 2. Aз adamantylphosphorinomethyl) benzene except using equimolar bis(l-adamantyl-tert-butyl 1,2 of amounts phosphor(borane)methyl) benzene instead of 1,2 bis)(diadamantylphosphor(borane)methyl) benzene.

10

Example 6

Preparation of 1,2 bis(di-1-diamantanephosphinomethyl) benzene. Diamantane = congressane



1,2 bis(dicongressylphosphinomethyl) benzene

15

6.1 Diamantane. This was synthesised according to the method of Tamara et al. Organic Syntheses, CV 6, 378

6.2 Di-1-(diamantane) phosphinic chloride. Prepared as per Di-1-adamantyl phosphinic chloride except using diamantane 20.0g (0.106 mol) and AlCl₃ (16.0g, 0.12 mol). Yield 25.5g FW: 456.5.. ³¹P NMR: δ: 87ppm (s).

5

6.3 Di-1-(diamantane) phosphine. Prepared as per Di-1-edamantyl phosphine except using 25.0 g Di-1-(diamantane) phosphinic chloride. Yield 14.0 g FW: 406.. 31 P NMR: δ : 16.5ppm (s).

10

6.4 Di-1-(diamantane) phosphine) trihydro boron. Prepared as per Di-1-adamantyl phosphine trihydro boron except using 15.0 g Di-1-(diamantane) phosphine. Yield 14.5 g.

15

- 6.5 Synthesis of 1,2 bis (diamantane phosphor (borane) methyl) benzene via deprotonation with secBuLi and reaction with an dichloro c-xylene. per 1,2 bis (di-1-adamantylphosphor(borane)methyl) 20 benzene except using an equimolar amount of diamantane trihydroboron phosphine instead ο£ di-l-adamantvl phosphine trihydroboron.
- 6.6 Synthesis οÉ 1.2 bis (diamantanephosphinomethyl) 25 benzene **E**iv deprotection ο£ 1,2 bis (diamantane (borane)methyl) benzene with HBF4'O(ME)2. Prepared as per 1,2 bis (di-1-adamantylphosphino methyl) benzene except using an equimolar amount οf 1,2 bis diamantine phosphor(borane)methyl) benzene instead of 1,2 bis(di-30 adamantylphosphor(borane)methyl) benzene.

Example 7

Preparation of 1,2-bis-(ditertbutylphosphinomethyl) benzene

1,2-bis-(di-tert-butylphosphinomethyl)benzene

The preparation of this ligand was carried out in the manner disclosed in WO 99/47528 in accordance with Example 18.

10

15

5

Example 8 (comparative)

Preparation of 1,3 bis(diadamantylphosphino) propane

Preparation of 1,3-bis-(di-1-adamantylphosphino)propane (2)

8.1 Preparation of (1-Ad) 2PL1

BuⁿLi (2.5 M in hexanes, 42.02 cm³, 105.1 mmol) was added dropwise via syringe to a stirred solution of Ad₂PH (10.59 g, 35.0 mmol) in THF (150 cm³). This resulted in a darkening of the solution to yellow and the precipitation of a large quantity of yellow solid, in a mildly

exothermic reaction. The reaction was stirred at ambient temperature for 3 h. The volatiles were removed in-vacuo, affording a very pale orange solid. The solid was washed with pentane (2 x 50 cm³) to remove excess Bu¹Li, resulting in the isolation of a white powder (washings orange) which was dried in-vacuo. The yield for this step was assumed to be quantitative, on the basis of previous NMR experiments.

8.2 Reaction of 1.3-dibromopropane with 2 equiv (1-Ad)2PLi 1,3-dibromopropane (degassed, 1.78 cm3, 17.5 mmol) was 10 added dropwise via syringe to a stirred suspension of Ad₂PLi (35.0 mmol, prepared as above) in THF (150 cm³). Initially a yellow solution was formed, then a great deal of white solid crashed out (product). The volatiles were removed in-vacuo and dichloromethane (300 cm3) added via 15 cannula affording a turbid solution. The turbidity was lost on addition of water (degassed, 100 cm3), a two phase system being formed. The lower phase was removed via cannula filtration. The volatiles were removed in-vacuo, affording a white powder, which was washed with pentane 20 (100 cm^3), dried and isolated in the glovebox. Yield 6.45 g, 57 %. 31P NMR: 5 = 24 ppm, 95+ % pure. FW = 644.94.

Example 9

25 Preparation of 1,2-bis-(dimethylaminomethyl) ferrocene

n-Butyllithium (Aldrich, 2.5 molar in hexane, 24 ml, mmol) is added to а solution of (dimethylaminomethyl) ferrocene (Aldrich, 13.13 g, mI, 48.97 mmol) in diethyl ether (80 ml) under nitrogen at 30 a temperature of 25°C and the reaction mixture stirred for 4 hours. The resulting red solution is then cooled to approximately -70°C in a dry ice/acetone bath

Eschenmosers salt (ICH_2NMe_2) (Aldrich, 10 g, 54 mmol) is added. The reaction is allowed to warm to room temperature and stirred overnight.

The resultant solution is quenched with excess aqueous 5 sodium hydroxide and the resulting product extracted with diethyl ether (3 x 80 ml) dried over anhydrous magnesium sulfate, filtered over celite, and volatiles removed in vacuo to yield the crude title compound as a light orange crystalline solid. The crude product is recrystallised 10 -17°C the cooling to petrol with light recrystallised product washed with cold petrol to yield the title compound as a light orange solid (13.2 g, 74%). The compound can be further purified by sublimation to give 8.5 g (52%) of the title compound (mpt 74°C). 15

¹H NMR(250 MHz; CDCl₃):54.23(brd. 2H); 4.11-4.10(t, lH); 4.04(a, 5H); 3.43, 3.38, 3.23, 3.18 (AB quartet, 2H); 2.22(s, 6H).

¹³C NMR (63 MHz; CDCl₃): 583.81; 70.40; 69.25; 66.84; 57.35; 45.23.

Elemental analysis: Found: C 63.7%; H 8.9%; N 9.5%

Calculated: C 64.0%; H 8.1%; N 9.4%

Example 10

20

Preparation of 1,2-bis-(ditertbutylphosphinomethyl) ferrocene

30 Di-tertbutylphosphine (Aldrich, 0.616 ml, 3.33 mmol) was added to a solution of 1,2-bis(dimethylaminomethyl)ferrocene (Example 9, 0.5 g, 1.66 mmol) in anhydrous acetic acid (100 ml) under nitrogen and

the resulting mixture is stirred at 80°C for 72 hours. The anhydrous acetic acid is removed in vacuo at approximately 70°C to yield the crude title product as an orange/yellow solid. The crude product is recrystallised from ethanol with cooling to -17°C, filtered and the filtrate washed with cold ethanol to yield the title compound as a pale yellow solid (0.365 g, 44%, 84°C).

¹H NMR (250 MHz; CDCl₃): 54.4 (2H, d, J = 2Hz); 3.95(5H, 10 s); 3.75 (1H, t, 2Hz); 2.8 (2H, dd, 12Hz, 2Hz); 2.6 (2H, dd, 12Hz, 2Hz); 1.1 (36H, m).

¹³C NMR (63 MHz; CDCl₃): 586.73 (d, 5.46 Hz); 70.08 (d, 4.41 Hz); 69.4665(g); 63.75(g); 31.80 (d, 2Hz); 31.45 (d, 1.98Hz); 29.89 (d, 1.88 Hz).

³¹P NMR (101 MHz; CDCl₃): δ15.00 ppm.

Elemental analysis: Found: C:66.79%; H:9.57%

Calculated: C:66.93%; H:9.63%

Example 11

25

Preparation of 1-hydroxymethyl-2-dimethylaminomethyl ferrocene

n-Butyl lithium (Aldrich, 1.6 molar in diethyl ether, 5.14 ml. 8.24 mmol) is added to a solution dimethylaminomethyl ferrocene (Aldrich, 1.0g, 4.12mmol) in diethyl ether (20mL) under argon. The reaction is stirred for 3 hours and develops a reddish colour. 30 The solution is then cooled in a dry ice/acetone bath, calcined paraformaldehyde (0.247g, 2 times excess) added and the resultant mixture stirred overnight at room temperature.

The reaction is then quenched with water, extracted with diethyl ether, dried over MgSO4, and filtered over celite. The solvent is removed in vacuo to yield crude title compound. The crude product is applied to a neutral alumina column, which is eluted with petrol/diethyl ether material, starting remove the ratio) to (9:1)dimethylaminomethyl ferrocene. The column is then eluted with substantially pure ethyl acetate to elute the title compound. The ethyl acetate is removed in vacuo, to yield the title compound as an orange oil/crystalline mass.

¹H NMR (250 MHz; CDCl₃) δ2.131 (s, 6 H), δ2.735 (d, 1 H, 12.512 Hz), δ3.853 (d, 1 H, 12.512 Hz), δ3.984 (dd, 1 H, 2.156 Hz), δ4.035 (s, 5 H), δ4.060 (dd, 1 H, 2.136 Hz) δ4.071 (d, 1 H, 12.207 Hz), δ4.154 (m, 1 H), δ4.73 (d, 1 H, 12.207 Hz).

¹³C NMR (61 MHz; CDCl₃) δ7.688, δ84.519, δ70.615, δ68.871, δ68.447, δ65.369, δ60.077, δ58.318, δ44.414

20

10

COSY 2D 1H NMR

Partly obscured doublet at 4.071ppm and its coupling to the doublet at 4.73 ppm confirmed.

Infrared spectra (CHCl₃) (c.a. 0.06g / 0.8mL)

25 2953.8 cm⁻¹, 2860.6 cm⁻¹, 2826.0 cm⁻¹, 2783.4 cm⁻¹, 1104.9 cm⁻¹

Example 12

Preparation of 1,2-bis-(ditertbutylphosphinomethyl) ferrocene

Di-tertbutylphosphine (Aldrich, 0.54 ml, 2.93 mmol) is solution φf 1-hydroxymethyl-2added to dimethylaminomethyl ferrocene (Example 11, 0.2 g, 0.753 mmol) in anhydrous acetic acid (15 ml) and acetic anhydride (0.753 mmol) under argon and the resulting mixture is stirred at 80°C for 72 hours. The anhydrous 10 acetic acid is removed in vacuo at approximately 70°C to yield the crude title product as an orange/yellow solid. The crude product is recrystallised from ethanol with cooling to -17°C, filtered and the filtrate washed with cold ethanol to yield the title compound as an orange solid (0.23 g) 15

¹H NMR (250 MHz; CDCl₃) δ4.351 (d, 2 H, 2Hz), δ4.022 (g, 5 H),δ3.827 (t, 1 H, 2 Hz), δ2.858 (ddd, 2 H, J_{HH} 15.869 Hz, J_{HP1}3.320 Hz, J_{HP2} 1.831 Hz), δ2.679 (dd, 2 H, J_{HH} 15.869 Hz, J_{HP} 2.441 Hz), δ1.166 (d, 18 H, 12.817 Hz), δ1.123 (d, 18 H, 12.512 Hz)

FTIR (Chloroform, NaCl plates)
1104.1 cm⁻¹, 2863cm⁻¹, 2896.0 cm⁻¹, 2940.0 cm⁻¹, 2951.8 cm⁻¹

31P NMR (101 MHz; CDCl3): 515.00 ppm.

Elemental analysis: Found: C:66.5%; H:9.6% Calculated: C:66.9%; H:9.6%

25

20

Example 13 Preparation of 1-hydroxymethyl-2,3-bis(dimethylaminomethyl) ferrocene

- 5 To a stirred solution of 1,2-bis-(dimethylaminomethyl) ferrocene (Example 9, 0.70g, 2.32 mmol) in diethyl ether (15 cm³) under argon is added 1.2 equivalents n-butyl lithium (Aldrich, 1.75mL, 1.6M in diethyl ether) and the mixture stirred for three hours to yield a red solution.
- The reaction mixture is cooled in a dry ice/acetone bath, calcined paraformaldehyde added in 2:1 excess, and the resultant mixture stirred at room temperature overnight. The mixture is quenched with water and extracted with diethyl ether. The ethereal extracts are dried over MgSO4,
- 15 filtered over celite and the solvent removed in vacuo, to yield the title compound (0.7g, 2.12 mmol, 91%) as an orange oil., which partially crystallized on cooling.
- ¹H NMR (250 MHz; CDCl₃) δ 2.133 (s, 6 H), δ 2.171 (s, 6 H), 20 δ 2.910 (d, 1 H, 12.817 Hz), δ 2.998 (d, 1 H, 12.512 Hz), δ 3.425 (d, 1 H, 12.817 Hz), δ 3.812 (d, 1 H, 12.512 Hz), δ 3.962 (s, 5 H), δ 3.99 (d, 1 H, 12.207 Hz) (partly obscured by large cp-ring peak at δ 3.962), δ 4.068 (d, 1 H, δ2.136 Hz), δ 4.125)d, 1 H, δ 2.136 Hz), δ 4.747 (d, 1 H, 12.207 Hz)
 - ¹³C NMR (60 MHz; CDCl₃) δ44.529, δ45.244, δ55.798, δ57.906, δ60.271, δ67.944, δ68.277, δ69.612, δ84.850, δ88.322
- 30 Infrared spectra (CDCl3 / thin film NaCl plates)

3380.6 cm⁻¹ (br), 2955.7 cm⁻¹ (m), 2862.6 cm⁻¹, 2825.9 cm⁻¹ (m), 2774.3 cm⁻¹ (m), 1353.5 cm⁻¹ (m), 1104.9 cm⁻¹ (m), 1038.9 cm⁻¹ (m), 1006.8 cm⁻¹ (s)

5 Elemental analysis: Found: C: 62.3%; H: 7.8%; N: 8.8% Calculated: C:61.8%; H:7.9%; N:8.5%

Example 14

Preparation of

10 1,2,3-tris-(ditertbutylphosphinomethyl) ferrocene

Di-tert-butylphosphine (Aldrich, 2.60 mL, 13.98 mmol) and acetic anhydride (0.24 mL, 2.33 mmol) is added to a 1-hydroxymethyl-2,3-bisοĒ solution (dimethylaminomethyl)ferrocene (Example 13, 0.70g, 2.12 15 mmol) in acetic acid (freshly distilled from acetic anhydride 25 cm^3), under argon. The solution is then stirred at 80°C for 7 days, during which time the solution becomes a dark orange colour. The solvent is then removed in vacuo and recrystallisation effected from refluxing 20 ethanol together with cooling to -17°C overnight to yield the title compound (0.43 g. 0.7 mmol, 31%) yellow/orange powder.

- 30 Infrared spectra (CHCl₃ / thin film NaCl plates) $1365.5~\rm{cm}^{-1},~1470.3~\rm{cm}^{-1},~2357.1~\rm{cm}^{-1}~,2862.8~\rm{cm}^{-1}~,~2896.7~\rm{cm}^{-1}~,~2939.1~\rm{cm}^{-1}$

Example 15

Preparation of 1,2-bis-(dicyclohexylphosphinomethyl) ferrocene

5

The title compound was prepared in accordance with the procedure of Example 10 employing dicyclohexylphosphine (Strem of 48 High Street Orwell, Royston, United Kingdom SG8 5QW, 659 mg, 3.33 mmol), 1,2-

10 bis (dimethylaminomethyl) ferrocene (0.5 g, 1.66 mmol) and anhydrous acetic acid (100 ml). Yield 0.421 g.

Example 16

Preparation of 1,2-bis-(di-iso-butylphosphinomethyl)

15 ferrocene

The title compound was prepared in accordance with the procedure of Example 10 employing di-iso-butylphosphine (Strem 486 mg, 3.33 mmol), 1,2-

20 bis(dimethylaminomethyl) ferrocene (0.5 g, 1.66 mmol) and anhydrous acetic acid (100 ml). Yield 0.372 g.

Example 17

<u>Preparation</u> of 1,2-bis-(dicyclopentylphosphinomethyl)

25 ferrocene

The title compound was prepared in accordance with the procedure of Example 10 employing dicyclopentylphosphine (Strem 566 mg, 3.33 mmol), 1,2-

30 bis(dimethylaminomethyl)ferrocene (0.5 g, 1.66 mmol) and anhydrous acetic acid (100 ml). Yield 0.432 g.

Example 18

Preparation of 1,2-bis-(diethylphosphinomethyl) ferrocene

The title compound was prepared in accordance with the procedure of Example 10 employing diethylphosphine (Strem 299 mg, 3.33 mmol), 1,2-bis(dimethylaminomethyl)ferrocene (0.5 g, 1.66 mmol) and anhydrous acetic acid (100 ml). Yield 0.254 g.

10 Example 19

Preparation of 1,2-bis(di-isopropylphosphinomethyl) ferrocene

The title compound was prepared in accordance with the procedure of Example 10 employing di-iso-propylphosphine (Digital Speciality Chemicals 392 mg, 3.33 mmol), 1,2-bis(dimethylaminomethyl)ferrocene (0.5 g, 1.66 mmol) and anhydrous acetic acid (100 ml). Yield 0.262 g.

20 Example 20

Preparation of 1,2-bis-(dimethylphosphinomethyl) ferrocene

The title compound was prepared in accordance with the procedure of Example 10 employing dimethylphosphine (Digital Speciality Chemicals, 206 mg, 3.33 mmol), 1,2-bis(dimethylaminomethyl)ferrocene (0.5 g, 1.66 mmol) and anhydrous acetic acid (100 ml). Yield 0.285 g.

Example 21

Preparation of 1,2-bis-(diadamantylphosphinomethyl) ferrocenebis-methanesulphonate

Di-adamantylphosphine (prepared according to J.R.Goerlich, R.Schmutzler; Phosphorus Sulphur and Silicon; 1995, 102, 211-215, 20.0g, 0.066 mol) was added to a solution of 1,2bis (dimethylaminomethyl) ferrocene (Example 9, 10 g, 0.033 5 mol) in anhydrous acetic acid (100 ml) under nitrogen and the resulting mixture is stirred at 80°C for 72 hours. The orange yellow precipitate which forms is filtered and dried in vacuo at approximately 70°C to yield the title compound as an orange/yellow solid. The title compound is insoluble in a range of organic solvents and it 10 bisthe ta conversion purified by therefore о£ addition by salt methanesulphonate methanesulphonic acid to a methanol slurry of the crude This resulted in complete dissolution of the product. product salt which was then isolated by removal of the 15 methanol in vacuo followed by washing with ether drying to give the title compound as a pale yellow solid (14.0g, 54%).

20 ¹H NMR (250 MHz; CD₃CN): 54.57 (2H, d, J = 2Hz); 4.35 (5H, s); 4.27 (1H, t, 2Hz); 3.34 (4H, br); 2.6 (6H, br,); 2.35-2.18 (18H br); 2.16-2.0 (18H, br); 1.92-1.72 (24H, br).

31P NMR (101 MHz; CD3CN): 526.58 ppm.

Elemental analysis: Found: C:64.15%; H:7.88% Calculated: C:64.29%; H:7.94%

Example 22

25

Preparation of 1,2 bis(di-1-adamantylphosphinomethyl)
ferrocene-bis-methane sulphonate

The preparation of this ligand was carried out as follows:

22.1 Preparation of (1-Ad)₂P(0)Cl

The di-l-adamantyl phosphine chloride was prepared in accordance with the method of Example 1.1.

22.2 Preparation of (1-Ad)2PH

The di-1-adamantyl phosphine was prepared in accordance with the method of Example 1.2.

22.3 Preparation of 1.2-bis(di-1-adamantylphosphinomethyl) ferrocene-bis-methanesulphonate

15 The title compound was prepared in accordance with the procedure exemplified in Example 21.

Example 23

30

Preparation of 1,2-bis(di-1-(3,5-dimethyladamantyl)

- 20 phosphinomethyl) ferrocene-bis-methanesulphonate
 - 23.1 Di-1-(3.5-dimethyladamantyl) phosphinic chloride was prepared in accordance with the method of Example 3.1.
- 25 23.2 Di-1-(3.5-dimethyladamantyl) phosphine was prepared in accordance with the method of Example 3.2.

23.3 1,2-bis-(d1-1-(3,5-dimethyladamantylphosphinomethyl) ferrocene-bis-methanesulphonate

The title compound was prepared in accordance with the procedure exemplified in Example 21 except using di-1-

2(3,5-dimethyl-adamantyl)phosphine (23.69 g, 0.066 mol) instead of di-adamantylphosphine. Yield 15 g.

Example 24

10

20

25

30

- 5 Preparation of 1,2-bis(di-1-(5-tert-butyl-adamantyl) phosphinomethyl) ferrocene-bis-methanesulphonate
 - 24.1 Di-1-(5-tert-butyladamantyl) phosphinic chloride was prepared as per Example 4.1 above.

24.2 Di-1-(5-tert-butyladamantyl) phosphine was prepared as per Example 4.2 above.

24.3 1,2-bis(di-1-(4-tert-butyl-adamantyl)

15 phosphinomethyl) ferrocene-bis-methanesulphonate

The title compound was prepared in accordance with the procedure exemplified in Example 21 except using di-1-(4-tert-butyladamantyl)phosphine (27.39 g, 0.066 mol) instead of di-adamantyl phosphine. Yield 14.52 g.

Example 25

Preparation of 1,2-bis-(1-adamantyl tert-butyl-phosphinomethyl) ferrocene-bis-methanesulphonate

25.1 1-adamantylphosphonic acid dichloride

This compound was synthesised according to the method of Olah et al (J. Org. Chem. 1990, 55, 1224-1227).

25.2 1-adamantyl phosphine

LiAlH₄ (3.5 g, 74 mmol) was added over 2 hours to a cooled solution (0°C) of 1-adamantylphosphonic acid dichloride (15 g, 59 mmol) in THF (250 cm³). The reaction was then allowed to warm to ambient temperature and was stirred for 20 hours. The grey suspension was then cooled (0°C) and HCl (75 cm³, 1M) was slowly added via syringe, to afford a two phase system with some solid present in the lower phase. Concentrated HCl (8 cm³, 11M) was then added to improve the separation of the two layers. The (upper) THF phase was removed via cannula and dried over magnesium sulphate. After filtration via cannula, the volatiles were removed in-vacuo to afford the product.

25.3 1-adamantyl tert-butyl phosphine

15

20

25

10

nBuLi (20 cm³, 32 mmol 1.6M soln) was added over 1 hour to a cooled solution of 1-adamantyl phosphine (5.0 g, 30 mmol) in THF (100 cm³). The solution was allowed to warm to room temperature and stirred for a further 2 hours. The solution was recooled to 0°C and tert-butylchloride (2.78 g, 30 mmol) was added and stirring continued for a further 16 hours at room temperature. The reaction mixture was quenched with water and the aqueous phase extracted with dichloromethane (2 x 50 ml). The organic phase was dried over sodium sulphate and evaporated in-vacuo to yield the title compound.

25.4 1,2-bis-(-1-adamantyl tert-butyl-phosphinomethyl) ferrocene-bis-methanesulphonate

30

The title compound was prepared in accordance with the procedure exemplified in Example 21 except using 1-

adamantyl tert-butyl phosphine (14.78 g, 0.066 mol) instead of di-adamantyl phosphine. Yield 9.80 g.

Example 26

25

Preparation of 1,2-bis-(di-1-diamantylphosphinomethyl) ferrocene-bis-methanesulphonate

26.1 Diamantane

10 This was synthesised according to the method of Tamara et al. Organic Syntheses, CV 6, 378.

25.2 Di-1-(diamantane) phosphinic chloride

Prepared as per Di-1-adamantyl phosphinic chloride of Example 1.1 except using diamantane 20.0 g (0.106 mol) and AlCl₃ (16.0 g, 0.12 mol). Yield 25.5 g FW: 456.5.. ³¹p NMR: ô: 87 ppm (s).

20 26.3 Di-1-(diamantane) phosphine

Prepared as per Di-1-adamantyl phosphine of Example 1.2 except using 25.0 g Di-1-(diamantane) phosphinic chloride. Yield 14.0 g FW: 406.. 31 P NMR: δ : 16.5 ppm (s).

26.4 1,2-bis-(di-1-diamantylphosphinomethyl) ferrocenebis-methanesulphonate

The title compound was prepared in accordance with the procedure exemplified in Example 21 except using di-1-diamantane phosphine (26.79 g, 0.066 mol) instead of di-adamantyl phosphine. Yield 12.5 g.

Example 27

Preparation of 1,2-bis-(di-(1,3,5,7-tetramethyl-6,9,10-trioxa-2-phospha-adamantylmethyl)) ferrocene

5 1,3,5,7-tetramethyl-2,4,8-trioxa-6-phospha-adamantane (obtained from Cytec, 14.0g, 0.066 mol) was added to a solution of 1,2-bis(dimethylaminomethyl)ferrocene (Example 9, 10 g, 0.033 mol) in anhydrous acetic acid (100 ml) under nitrogen and the resulting mixture is stirred at 80°C for 72 hours. The anhydrous acetic acid is removed in vacuo at approximately 70°C to yield the crude title product as an orange/yellow solid. This is washed with hot methanol to give the product as a mixture of isomers as an orange solid. (12.0 g, 58%).

¹H NMR (250 MHz; CDCl₃): 54.25-3.95 (8H, br, m); 3.46 (4H, br); 1.57-2.0 (8H, br, m); 1.43-1.23 (24H, br m).

³¹P NMR (101 MHz; CDCl₃): 5 -27.41 (br), -29.01 (s), -33.9 20 (br) ppm.

Elemental analysis: Found: C:57.80%; H:7.35% Calculated: C:57.87%; H:7.40%

25 Example 28

15

<u>Preparation of 1,2-bis-(dimethylaminomethyl)</u>ferrocene-bis methyl iodide

Methyl iodide (23.28g, 0.164 mol) is added to a solution of 1,2-bis-(dimethylaminomethyl) ferrocence (Example 9, 20g, 0.082 mol) in degassed methanol (100 ml), and the mixture stirred at room temperature under a nitrogen atmosphere for 24 hours. The resulting precipitate is

removed by filtration, washed with ether and dried to yield the title compound (43.0g).

Elemental analysis: Found: C:36.8%; H:5.1%; N,4.8%

Calculated: C:37.0%; H:5.2%; N,4.8%

¹³C NMR (D₂O): δ 53.27, δ 53.21, δ 53.15, δ 64.68, δ 71.77, δ 73.24, δ 74.13, δ 74.95

10 Example 29

5

<u>Preparation of 1,2-bis(dihydroxymethylphosphinomethyl)</u> ferrocene

Potassium hydroxide (8.52q, 0.152 mol) is added to a solution of tetrakis(hydroxymethyl) phosphonium chloride 15 (Aldrich, 38.54q of 80% w/w aqueous solution, 0.162 mol) in decassed methanol (40 ml), and stirred at room temperature under a nitrogen atmosphere for 1 hour. The resultant mixture is added dropwise to a decassed solution 20 1,2-bis-(dimethylaminomethyl)ferrocene-bis-methyl iodide (Example 28, 19.98g, 52.2 mmol) in methanol (40 ml) under nitrogen at room temperature with stirring. resultant mixture is refluxed under nitrogen for 20 hours, and the solvent removed in vacuo to form a red 25 precipitate. Water (30 ml), diethyl ether (85 ml) and triethylamine (35 ml) is added to the precipitate and the solution stirred at room temperature for 1 hour. aqueous layer is removed and re-extracted with diethyl ether (2 x 30 ml). The combined ethereal extracts are 30 washed with water (3 x 20 ml) dried over sodium sulphate and filtered. The ether is removed in vacuo to yield the crude title compound (14.33g, 948 yield) a microcrystalline orange solid. The crude product

recrystallised from a warm dicholormethane/methanol solution with the addition of light petroleum and cooling to yield the title compound (10.69g, 70% yield) as yello-orange crystals.

5

- Elemental analysis: Found: C:48.44%; H:4.12%; N.0.0%

 Calculated: C:48.24%; H:4.02%;

 N.0.0%
- 10 ¹H NMR: 51.75 (s, br), 52.70 (dd, 2 H, J^2_{HR} 14.2 Hz, J^2_{HP} 6.6 Hz), 52.85 (dd, 2 H, J^2_{HR} 14.2 Hz, J^2_{HP} 7.9 Hz), 53.71 (t, 1 H, J_{HR} 2.44 Hz), 53.58 (s, 5 H), 53.98 (d, 2 H, J_{HR} 2.40 Hz), 4.06 (m, 8 H).
- 15 ¹H{³¹P} NMR: 51.75 (s, br), 52.70 (d, 14.3 Hz), 52.85 (d, 14.3 Hz), 54.04 (m, 1 H), 54.05 (s, 8 H), 54.08 (s, 5H), 54.1 (m, 2 H)
- ¹³C NMR: 523.7 (d, J^{1}_{PC} 15.6 Hz), 563.0 (d, J^{1}_{PC} 15.6 Hz), 20 566.0 (s), 567.2 (d, J^{3}_{PC} 9.2 Hz), 569.6 (s), 582.6 (d, J^{2}_{PC} 14.7 Hz)

31P NMR: 5-14.7

25 Infrared spectra (CHCl₃ / thin film NaCl plates) 3337.8 cm⁻¹(st, br), further peaks 1104 cm⁻¹ 2929.0 cm⁻¹, 3603.7 cm⁻¹, 3683.7 cm⁻¹.

Example 30

Preparation of 1,2-bis(diphosphinomethyl) ferrocene

1,2-bis(dihydroxymethylphosphinomethyl)ferrocene (Example 29, 5.45g, 13.70 mmol) and sodium metabisulfite (5.21g,

27.4 mmol) is added to a two-phase solvent system consisting of distilled water (60 ml) and light petroleum (60 ml). The mixture is refluxed for 3 hours in air. The resultant mixture is cooled stirred and the aqueous layer removed. The organic layer is washed with distilled water and the organic solvent removed in vacuo to yield the title compound (2.66g, 70% yield) as an orange crystalline solid.

10 Elemental analysis: Found: C:51.65%; H:5.75%

Calculated: C:51.80%, H:5.76%

¹H NMR (250 MHz; CDCl₃): 5 2.7-2.8 (m, 4H), 5 3.17 (m, 2H), 5 3.18 (m, 2H), 5 4.04 (t, 1H, J=2.54 Hz), 5 4.09 (d, 5H, J_{HP} 0.4 Hz), 5 4.13 (d, 2H, J=2.54 Hz)

 31 P NMR (101 MHz; CDCl₃): 5 130.0 (t, J_{HF} 193.0 Hz)

¹³C NMR (60 MHz; CDCl₃): 8 12.9, 5 65.6, 5 67.3, 5 69.4, 5 20 86.9

¹³C DEPT NMR (CDCl₃): 5 12.9 (CH²), 5 65.6 (CH), 5 67.3 (CH), 5 69.40 (5 \times CH)

25 FTIR (Chloroform, NaCl plates): 2298.5 cm⁻¹ (strong)

Mass spectrum: Found m/z: 278.0088; Calculated m/z 278.0077

Example 31

Preparation

of

 $1,2-bis-\alpha,\alpha-(P-(2,2,6,6,-$

tetramethylphosphinan-4-one))dimethylferrocene

5

10

15

20

2,6-Dimethyl-2,5-heptadiene-4-one (14.5g, 0.106 mol) is added to 1,2-bis-(diphosphinomethyl) ferrocene (Example 30, 14.7g, 0.053 mol) and the mixture heated to 120°C under nitrogen for 20 hours. The reaction mixture is cooled, the crude title compound removed by filtration, washed with pentene (20 ml) and dried in vacuo to yield the title compound as a yellow-orange solid (24.9g, 85% yield). The title compound was characterised by ³¹P NMR and mass spectrum.

¹H NMR (250 MHz; CDCl₃): d 4.32 (1H, br); 4.08 (5H, br); 4.02 (1H, br); 3.94 (1H br); 2.84 (4H, br); 1.8-2.5 (8H, br); 1.05-1.4 (24H, br,).

31P NMR (101 MHz; CDCl3): 8 4.15 ppm.

Elemental analysis: Found: C:64.26%; H:7.88% Calculated: C:65.03%; H:7.94%

Example 32

5 Preparation of 1,2-bis-(di-1,3,5,7-tetramethyl-6,9,10-trioxa-2-phospha-adamantylmethyl))benzene

The preparation of this ligand was carried out in the manner disclosed in WO-A-03/070370 in accordance with Example 4 therein.

Example 33

15

Preparation of methyl propanoate from ethylene, carbon monoxide and methanol catalysed by a compound of the present invention

Condition 1 ratio of ligand:palladium = 5.2:1, ratio of acid:palladium = 160:1 and ratio acid:ligand = 30:1

20 Condition 2 ratio of ligand:palladium = 5.2:1, ratio of acid:palladium = 480:1 and ratio acid:ligand = 90:1

A mechanically stirred autoclave (Hastelloy) of 2 litre capacity was evacuated of air and then charged with a solution of tri(dibenzylideneacetone)dipalladium (1.44 x 10⁻⁵ moles), 1,2-bis-(di-tertbutylphosphinomethyl) ferrocene of Example 10, (7.61 x 10⁻⁵ moles) and methane sulfonic acid (2.30 x 10⁻³ moles condition 1, 6.90 x 10⁻³ moles condition 2) in 300 ml of methyl propanoate/methanol (70 wt% methyl propanoate). The autoclave was heated to 100°C and when at that temperature, ethylene (8 x 10⁵Nm⁻²) was added on top of the vapour pressure of the solvents and immediately an equimolar mixture of carbon monoxide

and ethylene (2 \times 10 5 Nm $^{-2}$) added to the system through a pressure regulating valve set to 10 \times 10^{5}Nm^{-2} above the solvent vapour pressure. Suitably, the molar ratio of the reactor monoxide in carbon to approximately 9:1. The temperature of the reactor was the reaction proceeded 100°C as maintained at and additional carbon monoxide and ethylene was added (on an equimolar basis) through the pressure regulating Tescom valve. No catalyst precipitation was observed.

10

Initial reaction rates measured in moles of methyl propanoate (MeP) per mole of palladium per hour and turnover measured in moles of methyl propanoate per mole of palladium were determined for the catalyst. This may be accomplished by an analysis of the amount of gas consumed per unit time (rate) and the total amount of gas consumed during the reaction, assuming ideal gas behaviour and 100% selectivity to methyl propanoate.

Table 1 shows the effect in increasing the relative acid 20 concentration compared to phosphine ligand concentration (and metal concentration) for a batch process on both the maximum initial rate and the turnover number (TON) after 1 hour, wherein initial reaction rates are measured in moles of methyl propanoate (MeP) per mole of palladium per hour 25 and TON is measured as moles of methyl propanoate per mole For both TON and maximum initial rate, of palladium. values are significantly increased passing from condition condition 2, i.e. when increasing both the to acid:ligand ratios at constant acid:palladium and 30 ligand:palladium values.

Table 1

### Rate (moles MeP/mole Pd) 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl) ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl)) ferrocene - condition 2 1,2-bis-(a-(-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 2 1,2-bis-qa-(P-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 1 1,2-bis-(di-(1,3,5,7-		Maximum Initial	Turnover Number
Pd/hr	7.	Rate	after 1 hour (moles
1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-(ad-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-(a,a-(P-(2,2,6,6,- tetramethylphosphinan-4- one))dimethylferrocene - condition 2 1,2-his-a,a-(P-(2,2,6,6,- tetramethylphosphinan-4- one))dimethylferrocene - condition 1		(moles MeP/mole	MeP/mole Pd)
butylphosphinomethyl) benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl)) ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl)) ferrocene - standard 1,2-bis-(di-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 2 1,2-bis-q,q-(F-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 1		Pd/hr)	
- condition 2 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl)) ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl)) ferrocene - standard 1,2-bis-(\(\alpha\cdot\)-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 2 1,2-bis-\(\alpha\cdot\)-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 1	1,2-bis-(di-tert-	66261	50786
1,2-bis-(di-tert-butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-tert-butylphosphinomethyl) benzene - condition 2 1,2-bis-(di-tert-butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-(1,3,5,7-tetramethyl-6,9,10-trioxa-2-phospha-adamantylmethyl)) ferrocene - condition 2 1,2-bis-(di-(1,3,5,7-tetramethyl-6,9,10-trioxa-2-phospha-adamantylmethyl)) ferrocene - standard 1,2-bis-(a,-(P-(2,2,6,6,-tetramethylphosphinan-4-cne)) dimethylferrocene - condition 2 1,2-bis-a,a-(P-(2,2,6,6,-tetramethylphosphinan-4-cne)) dimethylferrocene - condition 1	butylphosphinomethyl) benzene		
butylphosphinomethyl)benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-a,a-(P-(2,2,6,6,- tetramethylphosphinan-4- one))dimethylferrocene - condition 2 1,2-bis-a,a-(P-(2,2,6,6,- tetramethylphosphinan-4- one))dimethylferrocene - condition 1	- condition 2		
- condition 1 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 1 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-a,a-(P-(2,2,6,6,- tetramethylphosphinan-4- one))dimethylferrocene - condition 2 1,2-bis-a,a-(P-(2,2,6,6,- tetramethylphosphinan-4- one))dimethylferrocene - condition 1	1,2-bis-(di-tert-	42103	32397
1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl)benzene - condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-c,a-(P-(2,2,6,6,- tetramethylphosphinan-4- cne))dimethylferrocene - condition 2 1,2-bis-a,a-(P-(2,2,5,6,- tetramethylphosphinan-4- cne))dimethylferrocene - condition 1	butylphosphinomethyl)benzene		
butylphosphinomethyl) benzene - condition 2 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl)) ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl)) ferrocene - standard 1,2-bis-a,a-(P-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 2 1,2-bis-a,a-(P-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 1	- condition 1		
- condition 2 1,2-bis-(di-tert- butylphosphinomethyl) benzene - condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl)) ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl)) ferrocene - standard 1,2-bis-0,0-(F-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 2 1,2-bis-0,0-(F-(2,2,6,6,- tetramethylphosphinan-4- one)) dimethylferrocene - condition 1	1,2-bis-(di-tert-	94957	62635
1,2-bis-(di-tert-butylphosphinomethyl)benzene - cendition 1 1,2-bis-(di-(1,3,5,7-tetramethyl-6,9,10-trioxa-2-phospha-adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7-tetramethyl-6,9,10-trioxa-2-phospha-adamantylmethyl))ferrocene - standard 1,2-bis-\(\alpha\alpha\-(-\phi-(2,2,6,6,-tetramethyl-6,9,10-trioxa-2-phospha-adamantylmethyl))ferrocene - standard 1,2-bis-\(\alpha\alpha\-(-\phi-(2,2,6,6,-tetramethylphosphinan-4-t	butylphosphinomethyl)benzene		
butylphosphinomethyl) benzene	- condition 2		
- condition 1 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-\alpha(-(F-(2,2,6,6,- tetramethylphosphinan-4- condition 2 1,2-bis-\alpha(-(F-(2,2,5,6,- tetramethylphosphinan-4- condition 2 1,2-bis-\alpha(-(F-(2,2,5,6,- tetramethylphosphinan-4- condition 1	1,2-bis-(di-tert-	45421	29465
1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-\alpha(a-(F-(2,2,6,6,- tetramethylphosphinan-4- condition 2 1,2-bis-\alpha(a-(F-(2,2,6,6,- tetramethylphosphinan-4- condition 2 1,2-bis-\alpha(a-(F-(2,2,6,6,- tetramethylphosphinan-4- cone))dimethylferrocene - condition 1	butylphosphinomethyl)benzene		
tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-0,0-(F-(2,2,6,6,- tetramethylphosphinan-4- condition 2 1,2-bis-0,0-(F-(2,2,6,6,- tetramethylphosphinan-4- condition 2 1,2-bis-0,0-(F-(2,2,6,6,- tetramethylphosphinan-4- cone))dimethylferrocene - condition 1	- condition 1		
phospha- adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- 8490 4814 tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-\alpha.\alpha-(\beta-(2,2,6,6,- 29839 24270) tetramethylphosphinan-4- 29839 24270 one))dimethylferrocene - condition 2 1,2-bis-\alpha.\alpha-(\beta-(2,2,6,6,- 21591) 17676 tetramethylphosphinan-4- one))dimethylferrocene - condition 1	1,2-bis-(di-(1,3,5,7-		
adamantylmethyl))ferrocene - condition 2 1,2-bis-(di-(1,3,5,7- 8490 4814)) tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-\alpha,\alpha-(\text{F-(2,2,6,6,-} tetramethylphosphinan-4-} 29839 24270 one))dimethylferrocene - condition 2 1,2-bis-\alpha,\alpha-(\text{F-(2,2,6,6,-} 21591 17676}) tetramethylphosphinan-4- one))dimethylferrocene - condition 1	tetramethyl-6,9,10-trioxa-2-	55799	51997
- condition 2 1,2-bis-(di-(1,3,5,7- 8490 4814 tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-α,α-(P-(2,2,6,6,- 29839 24270 one))dimethylferrocene - condition 2 1,2-bis-α,α-(P-(2,2,6,6,- 21591 17676 tetramethylphosphinan-4- one))dimethylferrocene - condition 1	phospha-		
1,2-bis-(di-(1,3,5,7- tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-\alpha,\alpha-(P-(2,2,6,6,- tetramethylphosphinan-4- condition 2 1,2-bis-\alpha,\alpha-(P-(2,2,6,6,- 29839 24270 24270 29839 24270 21591 27676 21591 27676	adamantylmethyl))ferrocene		
tetramethyl-6,9,10-trioxa-2- phospha- adamantylmethyl))ferrocene - standard 1,2-bis-0,0-(P-(2.2,6,6,- tetramethylphosphinan-4- condition 2 1,2-bis-0,0-(P-(2,2,6,6,- tetramethylphosphinan-4- condition 2 1,2-bis-0,0-(P-(2,2,6,6,- tetramethylphosphinan-4- cone))dimethylferrocene - condition 1	- condition 2		
phospha- adamantylmethyl))ferrocene - standard 1,2-bis-a,a-(F-(2,2,6,6,- tetramethylphosphinan-4- one))dimethylferrocene - condition 2 1,2-bis-a,a-(F-(2,2,6,6,- tetramethylphosphinan-4- one))dimethylferrocene - condition 1	1,2-bis-(di-(1,3,5,7-	8490	4814
adamantylmethyl))ferrocene - standard 1,2-bis-\alpha,\alpha-(\beta-(2.2,6,6,-)) tetramethylphosphinan-4- condition 2 1,2-bis-\alpha,\alpha-(\beta-(2.2,6,6,-)) tetramethylphosphinan-4- cone))dimethylferrocene - condition 1	tetramethyl-6,9,10-trioxa-2-		
- standard 1,2-bis-\alpha.\alpha-(\text{P-}(2.2,6,6,-)) tetramethylphosphinan-4- condition 2 1,2-bis-\alpha.\alpha-(\text{P-}(2.2,6,6,-)) tetramethylphosphinan-4- one))dimethylferrocene - condition 1	phospha-		•
1,2-bis-a,a-(P-(2.2,6,6,- tetramethylphosphinan-4- condition 2 1,2-bis-a,a-(P-(2,2,6,6,- tetramethylphosphinan-4- one))dimethylferrogene - condition 1	adamantylmethyl))ferrocene		
tetramethylphosphinan-4- 29839 24270 one))dimethylferrocene - condition 2 1,2-bis-\alpha,\alpha-(P-(2,2,6,6,- 21591 17676))dimethylphosphinan-4- one))dimethylferrocene - condition 1	- standard		
one))dimethylferrocene - condition 2 1,2-bis-a,a-(P-(2,2,6,6,- 21591 17676 tetramethylphosphinan-4- one))dimethylferrocene - condition 1	1,2-bis-α,α-(P-(2.2,6,6,-		
condition 2 1,2-bis-a,a-(P-(2,2,6,6,- 21591 17676 tetramethylphosphinan-4- one))dimethylferrogene - condition 1	tetramethylphosphinan-4-	29839	24270
1,2-bis-a,a-(P-(2,2,5,6,- 21591 17676 tetramethylphosphinan-4- one))dimethylferrocene - condition 1	one) dimethylferrocene -		
tetramethylphosphinan-4- one))dimethylferrogene - condition 1	condition 2		
one))dimethylferrocene - condition 1	1,2-bis-α,α-(P-(2,2,6,6,-	21591	17676
condition 1	tetramethylphosphinan-4-		
	one))dimethylferrocene -		
1,2-bis-(di-(1,3,5,7-	condition 1		
	1,2-bis-(di-(1,3,5,7-	7 - 7 - 10 - 10 - 10 - 10 - 10 - 10 - 10	, m a mark

tetramethyl-6,9,10-trioxa-2-	29839	24270
phospha-		
7		
adamantylmethyl))benzene -		
condition 2		11444
1,2-bis-(di-(1,3,5,7-	12041	77444
tetramethyl-6,9,10-trioxa-2-		
phospha-		
adamantylmethyl))benzene -		
condition 1		
1,2-big-(di-(1,3,5,7-		
tetramethyl-6,9,10-trioxa-2-	20177	16610
phospha-		
adamantylmethyl))benzene -		
condition 2		
1,2-bis(di-1-		
adamantylphosphinomethyl)	67599	68141
ferrocene-bis-		
methanesulphonate -	as a	
condition 2		
1,2-bis(di-1-	41167	33798
adamantylphosphinomethyl)	*	
ferrocene-bis-		
methanesulphonate -		
condition 1		

Example 34

10

Pd(OAc)₂(22mg, 0.1mmol) and the respective phosphine ligand were weighed out in the inert atmosphere glove box into 500mL 3-neck round bottom flasks. On removal, 300mL of degassed MeOH were added and the mixture stirred for 1 solution methanesulphonic acid the 10mmol) was added. The weight of the catalyst solution was taken. The autoclave was charged with the solution and heated to 100C with stirring (3.0 barg vapour pressure). of The reaction started by the introduction was CO/ethylene (1:1) gaseous mixture to the autoclave. total pressure of the autoclave was controlled by a TESCOM

- (9.8 barg). This resulted in a 9:1 ratio of ethylene to CO. The temperature and pressure were maintained 3 hours during which period these values were recorded.
- 5 The gases were isolated and the unit cooled to room temperature. The depressurised unit was emptied and the final weight of the solution taken.

Ligand 1 = 1,2-bis(di-tert-butylphosphinomethyl)benzene

10

Ligand 2 = 1,2-bis(di-tert-butylphosphinomethyl) ferrocene

Ligand 3 = 1,2-bis(diadamantylphosphinomethyl)ferrocene

15 Ligand 4 = 1,2-bis(diphospha-adamantylphosphinomethyl)ferrocene

Ligand 5 = 1,3-bis(di-tert-butylphosphino)2-methylenepropane (comparative), prepared as in WO-A-03/040159 20 (Example 1 therein).

The results are shown in the tables below.

Table 2

25

Ligand	Ratio	Wt Gain	Avg. Wt Gain
	Pd:Lig:Acid	(g)	(g)
1	1:5:100	268.65	······································
1	1:5:100	244.47	
1	1:5:100	258.98	257.304
1	1:5:100	252.13	
1	1:5:100	262.29	

Table 3

Ligand	Ratio	Wt Gain	Avg. Wt. Gain	
	Pd:Lig:Acid	(g)	(g)	
2	1:5:100	302.64		
2	1:5:100	306.84		
2	1:5:100	293.4	300.9	
2	1:5:100	303.09		
2	1:5:100	298.54		

5

Table 4

Ligand	Ratio	Wt gain	Avg Wt Gain
	Pd:Lig:Acid	(g)	(g)
. 3	1:5:100	364.97	
3	1:5:100	340.18	347.54
3	1:5:100	345.15	
3	1:5:100	339.88	

Table 5

10

Ligand	Ratio	Wt gain	Avg Wt Gain
	Pd:Lig:Acid	(g)	(g)
4	1:5:25	126.31	
4	1:5:100	165.21	
4	1:5:100	189.83	
4	1:5:300	221.61	Av 1:5:300
4	1:5:300	261.28	249.67
4	1:5:300	281.81	•
4	1:5:300	233.99	

Table 6

Run No.	Ligand	Wt gain (g)	Ratio Pd:Lig:Acid
1.	5	33.3	1 ; 5 : 100
2	5	83.16	1:1:100
3ª	5	165.1	1:1:4
4ª	5	235.97	1:1:4
5ª	5	82.53	1 : 6 : 4

a) run at 3 x palladium concentration {67.3 mg Pd(OAc)2}

For the ligand 1,3-bis(di-tert-butylphosphino)2-methylenepropane (ligand 5) additional ligand with or without
excess acid results in a drop in catalyst performance.
The optimum conditions of low ligand and acid, e.g. Run
Nos. 3 and 4, result in the highest catalyst productivity
under the conditions studied. Addition of excess ligand
at high acid ratio as in Run No. 1 results in a
significant drop in performance, as does addition of
excess ligand at low acid ratios.

The following two tables contain data for the ligand 1,2-Bis(di-tert-butylphosphinomethyl)benzene. The data was collected at 80C hence the rates and turnover numbers are lower than the data we have already included. However, the data shows that at constant acid:ligandb levels, an increase in ligand:Pd ratio provides large increases in initial rate and TON values. This data also used the preformed catalyst [(L-L)Pd(dba) (for datails see below) and adds the ligand excess as the protonated salt. The experimental detail is provided below.

Table 7

Ligand	Ratio Pd:Lig:Acid	Ratio Acid:Ligand ^b	Initial rate	TON after 4 hours
i	1:5:36	10.9	5000	12000
1	1:5:72	20	17000	25000
1.	1:5:143	37	22000	30000

b in this ratio the "acid" includes both the acid from the protonated phosphine ligand together with the additional acid added (i.e., "free" acid) and the ligand is simply the protonated phosphine ligand.

Table 8

10

Ligand	Ratio Pd:Lig:Acid	Ratio Acid:Ligand ^b	Initial rate	TON after 4 bours
1	1:10:90	10.9	22000	42000
1.	1:10:182	20	33000	52000
1	1:10:352	37	41500	71000

The number of moles of palladium is equal to the number of moles of L_2Pd (dba).

The work described in these examples was carried out in 2L 15 In each test 10mg of L,Pd(dba) capacity autoclaves. catalyst and 32mg (4 equivalents) or 72mg (9 equivalents) of protonated phosphine were added to the preparation 175mL of azeotrope flask in a nitrogen purged glove box. product consisting of 50:50 wt% methanol and methyl 20 propanoate and 125mL of methyl propanoate were then degassed and added to the flask to provide a reaction solution which was close to 70wt% methyl propanoate. quantity required addition of the After methanesulphonic acid the solution was transferred to the 25

evacuated autoclave and heated to 80°C in vacuo. During this period and at all subsequent times the autoclave was stirred at ~1000 r.p.m. When this temperature had been reached the total pressure of the system was increased to 9 bar (from the vapour pressure baseline of ~1 bar) by the addition of ethylene and then topped up with 2bar of 1:1 C2H4/CO such that the total pressure was ~11bar and the headspace C2H4/CO ratio was 9:1. After this time only the 1:1 gas was fed to the system at the rate which was required to hold the pressure within the system constant. Reaction rates and catalyst TONs were calculated from the rate of removal of gas from the feed reservoir assuming ideal gas behaviour and 100% selectivity for methyl propanoate formation.

15

10

Preparation of 1,2-bis(di-1-adamantylphosphinomethyl)benzene palladium (dba)

THF (100 cm³) was added to a combination of ligand (2.05 g, 2.90 mmcl) and palladium dba (1.61 g, 2.90 mmcl [Pd]) 20 affording a deep red-orange turbid solution. The reaction stirred for 3 h. The reaction was filtered via cannula, yielding a deep red-orange filtrate and a small quantity of [Pd] residue. The volatiles were removed invacuo affording a deep red powdery solid. Pentane (50 cm³) 25 was added via cannula and attrition performed with a spatula, resulting in an orange powder separating out. The amber pentane washings were removed via filtration, and the solid washed with Et₂O at -10 °C (3 \times 50 cm3). The resultant orange powder was dried in-vacuo 30 and isolated in the glovebox. Yield 2.68 g, 88 %, 31P NMR:

Figure 1





Figure 2



		*	
			ï.
·			
		,	

Figure:3

